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This thesis is based on the following two research articles, which are referred to 
in the text by their roman numerals: 
 
 
I:  Kivioja JL, Lopez Martí JM, Kumar A, Kontro M, Edgren H, 
 Parsons A, Lundán T, Wolf M, Porkka K, Heckman CA (2018).
 Chimeric NUP98-NSD1 transcripts from the cryptic t(5;11)
 (q35;p15.4) in adult de novo acute myeloid  leukemia. Leukemia 
 & Lymphoma. 2018 Mar; 59 (3): 725-732. 
 
 
II: Kivioja JL, Thanasopoulou A, Kumar A, Kontro M, Yadav B, 
 Majumder MM, Javarappa KK, Eldfors S, Schwaller J, Porkka K, 
 Heckman CA. Dasatinib and navitoclax act synergistically to target 
 NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia. Leukemia. 
 2018 Dec 19. doi: 10.1038/s41375-018-0327-2. (Epub ahead of 
 print) 
 
 
The original articles were reproduced with permission from Taylor & Francis 
Group (Article I), and Nature Publishing Group (Article II). 
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ALL  Acute lymphoblastic leukemia 
Allo-HCT  Allogeneic hematopoietic cell transplant 
AML  Acute myeloid leukemia  
APL  Acute promyelocytic leukemia 
BCL-2  B-cell lymphoma-2 
BM  Bone marrow 
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CGH  Comparative genomic hybridization 
CML  Chronic myeloid leukemia 
CN-AML  Cytogenetically normal AML 
COG  Children’s Oncology Group 
CPM  Counts per million reads 
CR  Complete remission 
del  Deletion 
DMSO  Dimethylsulfoxide 
DNA  Deoxyribonucleic acid 
DSRT  Drug sensitivity and resistance testing 
DSS  Drug sensitivity score 
EC50  Half-maximal effective concentration 
ELN  European LeukemiaNet 
EMA  European medicines agency 
EMD  Extramedullary disease 
FAB  The French-American-British classification system 
FDA  Food and drug administration 
FG  Phenylalanine Glycine 
FISH  Fluorescence in situ hybridization 
FLT3  Fms-like tyrosine kinase 3   
GFP  Green Fluorescent Protein 
GO  Gemtuzumab ozogamicin 
HDAC  Histone deacetylase 
HMT  Histone methyltransferase 
HOX  Homeobox 
HPC  Hematopoietic progenitor cell 
HSC  Hematopoietic stem cell 
HSP90  Heat shock protein 90 
IC50  Half-maximal inhibitory concentration 
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Inv  inversion 
ITD  Internal tandem duplication 
LB  Luria broth 
LSC  Leukemic stem cell 
MAPK  Mitogen activated protein kinase 
MDS  Myelodysplastic syndrome 
MEK  Mitogen activated protein kinase kinase 
MNC  Mononuclear cell 
MLL  Mixed lineage leukemia 
MRD  Minimal residual disease 
MTOR  Mammalian target of rapamycin kinase 
NCBI  National Center for Biotechnology Information 
NCCN  National Comprehensive Cancer Network 
NGS  Next-generation sequencing 
NSD1  Nuclear receptor binding SET-domain protein 1 
NUP98  Nucleoporin 98 
OS  Overall survival 
p  Short arm of chromosome  
PCR  Polymerase chain reaction 
q  Long arm of chromosome  
RNA  Ribonucleic acid 
SET  Su(var)3-9, Enhancer of zeste and Trithorax 
t  Translocation  
t-AML  Therapy-related AML 
TCGA  The Cancer Genome Atlas 
TKI  Tyrosine kinase inhibitor 
WBC  White blood cell 
WHO  The World health organization 
WT1  Wilm’s tumour 1 
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The objective of this thesis was to facilitate molecular detection and treatment of 
acute myeloid leukemia (AML) patients with recurrent t(5;11)(q35;p15.4) 
translocation, which joins nucleoporin 98 (NUP98) and nuclear receptor binding 
SET-domain protein 1 (NSD1) genes together. These patients suffer from a 
malignant disease with highly unfavorable prognosis and no evidence regarding 
efficient therapeutic options.   
 
In study I, we investigated NUP98-NSD1 transcript variants from AML patients 
with t(5;11) to facilitate its molecular detection from newly diagnosed AML 
patients and from post-treatment samples. We focused on this topic since, 
comparably to many AML-defining translocations, the detection of t(5;11) relies 
on accurate molecular screening methods. This translocation cannot be captured 
using conventional cytogenetics (G-banding) due to its subtelomeric localization 
and small size. Moreover, potential for alternative fusion transcripts may further 
complicate detection of NUP98-NSD1. In this study, we discovered three chimeric 
NUP98-NSD1 transcripts from an index patient, which were later validated from 
two additional patients. The transcripts harbored two alternative fusion junctions 
joining NUP98 exon 11 or exon 12 to NSD1 exon 6, alternative 5’ donor site of 
NUP98 exon 7, and skipping of NSD1 exon 7. Intriguingly, relative frequency of 
the previously unknown fusion gene between NUP98 exon 11 and NSD1 exon 6 
was found to increase in two patients during disease progression.  
 
In study II, our aim was to identify novel, more efficient, and less toxic small-
molecule inhibitors for the treatment of NUP98-NSD1+ AML using high-
throughput drug sensitivity and resistance testing together with RNA sequencing. 
By screening over 300 anti-cancer drugs on patient cells and experimentally 
generated mouse cell models, we found that multikinase inhibitor dasatinib and 
pan-BCL-2 inhibitor navitoclax effectively and specifically target BM MNCs 
expressing NUP98-NSD1 and FLT3-ITD. In combinatorial drug screens, strong 
synergistic interactions were found between dasatinib and navitoclax. Gene 
expression analysis revealed up-regulation of genes encoding for targets of 
dasatinib and navitoclax, LCK, FGR, and BCL2A1. Furthermore, we discovered 
that NUP98-NSD1+/FLT3-ITD+ BM MNCs are highly resistant to topoisomerase 
II inhibitors such as mitoxantrone. It remains to be investigated whether replacing 
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topoisomerase II inhibitors with dasatinib and navitoclax in AML induction 
therapy could lead to improvements in long-term survival in patients with NUP98-
NSD1 and concomitant FLT3-ITD. 
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Acute myeloid leukemia (AML) has the worst survival rate of adult leukemias and 
remains among the most lethal cancers worldwide (1). The aggressive nature of 
AML results from a runaway proliferation of undifferentiated myeloid stem cells 
in the bone marrow (BM), which obstructs normal hematopoiesis. AML is 
generally a disease of elderly affecting mostly individuals of sixty-five years of 
age and older. In older patients (> 60 years), the 5-year overall survival (OS) rate 
is 10%, while it is roughly 40% in younger AML patients (< 60 years) (2). Due to 
population ageing, incidence of AML is expected to rise in Finland in the future. 
 
The first cancer genome was sequenced in 2008 from a patient with AML (3) and 
since then, the AML-defining genomic and transcriptomic alterations have been 
comprehensively characterized (4, 5). Technological advances have shifted the 
bottleneck hindering development of more efficient drugs from lack of genomic 
information to current inefficiencies in translating the excessive information into 
useful diagnostic and prognostic biomarkers, predicting treatment responses, and 
developing molecularly targeted therapies. Translational challenges related to 
drug development cover variety of factors such as limitations of preclinical drug 
screening methods, undruggable mutations, and unfeasibility to develop drugs 
against infrequent alterations (6). Regardless of the hindrances, many exciting 
discoveries have shed light on the remarkable potential of personalized genomic 
medicine. The best-known examples of successfully designed targeted therapies 
against oncogenic fusion genes include imatinib for chronic myeloid leukemia 
(CML) with BCR-ABL1 (7), all-trans retinoic acid for acute promyeloid leukemia 
(APL) with PML-RARA (8), and crizotinib for non-small cell carcinoma with 
EML4-ALK fusion gene (9). 
 
While approximately 300 gene fusions are known in AML (10), only few of them 
have been functionally characterized and investigated as therapeutic targets. To 
tackle this challenge, we centered our attention on high-risk NUP98-NSD1 fusion, 
which results from t(5;11)(q35;p15.4) translocation. This translocation is 
undetectable with traditional chromosome banding due to its cryptic nature and 
subtelomeric localization. An earlier study performed on myelodysplastic 
syndrome (MDS) patient with t(5;11) had detected two alternative NUP98-NSD1 
transcripts indicating that alternative transcripts exist and complicate molecular 
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monitoring of the fusion gene (11). To address this issue, we investigated whether 
novel NUP98-NSD1 variants could be found in AML. The objective of study I 
was to ensure that presence of t(5;11) is accurately captured from newly diagnosed 
AML patients and during minimal residual disease (MRD) monitoring. In study 
II, we investigated NUP98-NSD1 as a potential target for therapeutic modulation, 
since these patients are notoriously chemoresistant and lack adequate medical 
treatment options. 
 
In this thesis, we show evidence that RNA sequencing (RNA-Seq) is a powerful 
method for identifying novel fusion transcripts and gene expression changes that 
may be followed-up by targeted molecular screening methods. We also 
demonstrate that drug sensitivity and resistance testing (DSRT) assay is a sensitive 
preclinical screening assay for identifying molecularly specific drug responses for 
patients with recurrent fusion genes such as NUP98-NSD1.  
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The first publication regarding AML appeared in 1827 when a French surgeon 
named Alfred-Armand-Louis-Marie Velpeau reported his findings regarding an 
elderly man with fever, urinary stones, weakness, and enlarged liver and spleen 
(12). Along with these pathological features, the patient’s blood appeared as 
porridge-like, filled with white corpuscles. Some years later, the condition was 
named ”leucocythemia” by J.H. Bennett who discovered differences in color and 
composition of blood between patients (13). In 1856 Rudolf Virchow detected 
abnormally high levels of leukocytes from a patient’s blood using light 
microscopy and introduced the term ”leukemia”, which evolved from Greek word 
leukós (light in color, white) (14). Tracing the footsteps of earlier pioneers, Franz 
Neumann uncovered that leucocytes are made in the BM and introduced the term 
”myeloid” in accordance with the Greek word muelós (marrow). Another key 
discovery of the 19th century was made by Wilhelm Ebstein who noticed that 
myeloid leukemias can progress either slowly or fast and thereby suggested the 
term ”acute leukemia” for rapidly progressing leukemias (15). 
 
These early pioneers established a foundation to the whats, whys and wherefores 
of AML. Namely, to disease in which the ability of BM to replenish pools of 
differentiated hematopoietic cells has been stripped away by immature, yet 
exponentatially dividing leukemic cells. Consequently, the number of 
erythrocytes, platelets, neutrophils, and mature leucocytes plummet leading to 
chaotic stem-cell landscape and eventual BM failure. The lack of terminally 
differentiated cells (Figure 1) lead to various complications including fatigue, loss 
of apetite, infections, bruising, fever, blood clotting problems, and anemia (16). 
Although the malignant flock of descendants mainly accumulate in BM and blood, 
extramedullary disease (EMD) is found from roughly 25% of patients (17). EMD 
is most regularly present in patients with monocytic/myelomonocytic leukemia 
and in patients with high WBC counts (18). The most commonly infiltrated sites 
are lymph nodes, spleen, lungs, liver, skin, testicles, gingiva, and central nervous 
system, but PET/CT scans have identified as many as 55 distinct EMD sites. EMD 
is associated with lower CR and OS rates in AML (19).    
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Figure 1 Maturation of blood cells. The schematic drawing shows morphological features 
of various hematopoietic cells of myeloid origin at different stages of maturation. In AML, 
the terminal differentiation is ceased by various genomic alterations that occur in multi-
potent HSCs or in the committed myeloid progenitors. Adapted from online source (20) 
9/414->
The exact etiology of how mutations arise and lead to AML remain elusive 
although many known and suspected risk factors exist. Associated risk factors 
include cigarette smoking (21), exposure to diesel and gasoline, glues, adhesives, 
paints, inks, pigments, pesticides and fertilizers, formaldehyde, chloramphenicol, 
radiation, and exposure to electric and magnetic field (22-25). Previous anti-
cancer therapies have also been associated with increased likelihood of therapy-
related AML (t-AML). The specific cancer treatments that may lead to AML-
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causing mutations include type II topoisomerase inhibitors, alkylating agents, 
radioimmunotherapy, radiotherapy or their combination (26, 27). In a Danish 
study, 6.6% (203/3055) of AMLs were shown to have originated from previous 
anti-cancer therapy (28). True incidence of t-AML may be closer to 10% based 
on other studies (29).  
 
Aside from environmental risk factors, AML may develop from inherited genetic 
alterations. Germline alterations occasionally predispose individuals to various 
hematological malignancies that later progress to AML. Up to now, at least 13 
genetic diseases are known to occasionally develop into AML and include 
diseases such as Fanconi Anemia, Dyskeratosis congenita, Diamond Blackfan 
anemia, Li Fraumeni, Bloom syndrome, and Schwachman Diamond Syndrome 
(30). Wartiovaara-Kautto et al uncovered 34 germline variants from 16 genes that 
may predispose individuals to AML by exploring inherited mutations from 68 
patients  (31). Interestingly, 13% (8/62) of those AML patients had a close relative 
with a hematological disease. The list of most well-known predisposing germline 
variants include mutations in ASXL1 (32), DDX41 (33), CEBPA (34), GATA2 
(35), RUNX1 (36), TP53 (37), and trisomy 21 (38). Moreover, many other 
germline variants have been discovered from patients with AML and leukemia-
associated predisposition syndromes. Interestingly, percentage of inherited AML 
may be lower in children than in adults. In a recent study, inherited mutations were 
found from 13 genes of 4% of pediatric AML patients (n = 588) (39). 
 
Researchers have spent vast amount of time trying to reliably define the cell of 
origin in AML to generate knowledge about disease etiology and to facilitate the 
development of more efficient treatments. Current consensus is that AML arises 
as a result of multistep process (Figure 2). Mutations are acquired in the 
hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs) that 
normally yield erythrocytes, platelets, neutrophils, eosinophils, basophils, 
monocytes, T and B lymphocytes, natural killer cells, and dendritic cells. While 
there are examples of distinctive AML with low mutational burden in young 
patients, such as trisomy 21 (40), multistep leukemogenesis is most apparent from 
patients with germline mutations as these cases occasionally develop AML later 
in life after a long latency period (41).  
 
Next generation sequencing (NGS) experiments have revealed that multipotent 
HSCs harbor clones with recurrent founder mutations in genes involved in global 
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chromatin changes (e.g. DNMT3A, CEBPA, TET2, ASXL1, IDH1/2, IKZF1, 
SMC1A, CBFB-MYH11). Moreover, fusion genes are known to arise in the early 
stages of tumorigenesis (42). While HSCs of AML patients sometimes carry 
founder mutations such as fusion genes, they predominantly lack proliferative 
driver aberrations such as NPM1, FLT3-ITD, FLT3-TKD, KRAS/NRAS, or WT1 
that are predominantly found from the more committed HPCs (43-46). 
Accordingly, the initial founder alterations causing preleukemic state have been 
shown to occur in HSCs and are generally retained at relapse, while the leukemia 
initiating, driver mutations more frequently arise in committed HPCs such as in 
granulocyte/macrophage progenitors, common myeloid progenitors or lymphoid 
primed multipotent progenitors and are frequently lost at relapse  (47-50). Based 
on recent evidence, a subgroup of human AMLs may also arise from T-lymphoid 
progenitors with multi-lineage potential (51).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Suggested schemes of leukemogenesis. The drawing illustrates three alternative 
schemes of how AML arises (A-C). Founder mutations (1.) may strike either HSCs (blue) 
or myeloid progenitors (green) leading to preleukemic stage. Secondary driver mutations 
(2.) predominantly strike more committed HPCs (orange) and give rise to LSCs, which 
turn into leukemic blasts (red). Adapted from Walter et al, Blood, 2012 (52).    
 
Shlush et al identified preleukemic HSCs with founder mutations from patients in 
remission indicating that these cells have no response to chemotherapy (43). 
Similar to preleukemic HSCs, chemoresistance is a known feature of leukemic 



 

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stem cells (53). In vitro studies have provided evidence showing that AMLs 
arising from HSCs are significantly more chemoresistant and aggressive than 
AMLs arising from HPCs (54, 55). Experimental results have also been presented 
showing that AML patients whose granulocyte/macrophage progenitors carry 
higher number of HSC-specific mutations have the shortest survival after standard 
chemotherapy treatment (48). Consistent with the above-mentioned findings, 
immunophenotyping data from over 200 AML patients showed that high (>1%) 
CD34+/CD38- blast count, representative of HSC population, correlates strongly 
with lower post-induction CR rate and shorter disease-free survival (56). Taken 
together, the above-mentioned findings suggest that therapy and future drug 
development efforts should be steered toward targeting recurrent founder 
mutations in preleukemic HSCs or leukemic stem cells (LSCs) rather than 
proliferative driver mutations.  
 
In most patients, disease etiology cannot be traced back to a specific exposure or 
inherited genomic alterations. Researchers have postulated that due to the high 
age of patients at disease-onset, many AML causing mutations may be random 
events that accumulate during lifetime as a result of endogenous processes. In a 
landmark work published in 2012, Welch et al found that mutations in HPCs 
accumulate as a function of age (47). More au courant study has pinpointed that 
clonal hematopoiesis, driven by mutations, increases from 0.8% in individuals 
below 60 years of age to 19.5% in those who are 90 years of age and above (57). 
These findings are supported by other reports showing that newly diagnosed AML 
patients have, on average, three mutations (range 0-9) and that older AML patients 
usually carry at least one more mutation than younger patients (5, 58).  
/'-348/8'3*)1'88/,/)'9/43
During 2011-2015, 967 individuals (475 men and 492 women) were diagnosed 
with AML in Finland. Of those patients, 65.3% (632/967) were above 65 years of 
age highlighting that AML is a disease of old age (59). Similar observations have 
been made in other countries. In the National Cancer Institute (NCI) surveillance, 
epidemiology and end result (SEER) program of the United States, 57.4% of AML 
patients (SEER 18, 2011-2015) were 65 years or more with a median age of 68 at 
diagnosis (60). In United Kingdom, 3126 AML cases were diagnosed in 2015 with 
66.5% of them being above 65 years of age (61). The American Cancer Society 
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estimated that 19,520 new AML patients will be diagnosed in the United States in 
2018 (62), but the exact count has not been released yet.  
 
To meet diagnostic criteria for AML, 20% or more blasts (myeloblasts, 
monoblasts, promonocytes, or megakaryoblasts) should be detected from smears 
of 500 BM nuclear cells or ≥ 200 blood leucocytes after May-Grünwald-Giemsa 
or a Wright-Giemsa staining (63, 64). Lower blast counts are sufficient for AML 
diagnosis if patient carries leukemia-associated mutations (NPM1, CEBPA, 
RUNX1, FLT3, TP53, or ASXL1) or cytogenetic abnormalities such as t(15;17), 
t(8;21), inv(16), or t(16;16) listed on the 2016 WHO classification of myeloid 
neoplasms and acute leukemia (65).  
 
Many recurrent cytogenetic lesions are detected by mandatory cytogenetic 
analysis, which should be done with at least 20 BM metaphases. In case of 
negative result, fluorescent in situ hybridization (FISH) is frequently used for 
identifying high-risk patients. Quantitative reverse transcription polymerase chain 
reaction (qRT-PCR) and NGS are routinely used with dedicated gene panels to 
screen for cryptic translocations and mutations (66). The molecular tests are 
highly relevant, not only for disease classification and prognostication, but also 
for generating a treatment plan and taking measures for disease prevention. In 
addition to molecular genetic tests, immunophenotypic analyses (flow cytometry) 
and light microscopy are routinely utilized for determining affected cell lineage 
with various cell-surface and cytoplasmic markers as shown on Table 1 (65, 67). 
Exome and RNA sequencing has not been adapted to routine diagnostics due to 
many prevailing challenges related to discrimination of leukemia-related 
mutations from passenger mutations, germline alterations or PCR-related 
artefacts, limited sensitivity regarding MRD, and cost (68). 
 
Table 1. Immunophenotypic markers and cytochemistry used for the diagnosis of AML 
(Döhner et al modified).  
Lineage Markers 
A
M
L 
Precursors CD34, CD117, CD33, CD13, HLA-DR 
Granulocytic CD65, cytoplasmic myeloperoxidase 
Monocytic CD14, CD36, CD64 
Megakaryocytic CD41 (glycoprotein IIb/IIIa), CD61 (glycoprotein IIIa),  
Erythroid CD235a (glycophorin A), CD36 
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Newly diagnosed AML patients are classified based on cellular morphology and 
genetic abnormalities using two different classification schemes. The French-
American-British (FAB) classification (Table 2), introduced in 1976, divides 
AML patients into eight different disease entities (M0-M7) according to cell 
morphology and cellular response to histochemical stains (69-71). FAB system is 
progressively being replaced by the WHO classification scheme (Table 2), which 
was established in 2001 (72). The FAB system, however, remains a useful 
complementary assay for patient classification. Contrary to FAB classification, 
WHO classification is based on causality rather than effect (morphology) and 
therefore is likely to be more accurate and clinically relevant system. WHO 
recognizes six classes including (i) AML with recurrent genetic abnormalities, (ii) 
AML with myelodysplasia-related changes, (iii) therapy-related myeloid 
neoplasms, (iv) AML not otherwise specified, (v) myeloid sarcoma, and (vi) 
myeloid proliferations of Down syndrome (73, 74). It is likely that in the near 
future all AML patients will be classified based on genetic abnormalities, although 
a fraction of AML patients currently exist with no known driver mutations (5). 
 
 
Table 2. WHO and FAB classification of AML and related malignancies. 
WHO Classification Features 
1. AML w/ recurrent genetic abnormalities t(8;21)(q22;q22.1); RUNX1-RUNX1T1, inv(16)(p13.1;q22) or 
t(16;16)(p13.1;q22); CBFB-MYH11, APL with PML-RARA, 
t(9;11)(p21.3;q23.3); MLL3-KMT2A, t(6;9)(p23;q34.1); DEK-NUP214, 
inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); GATA2/MECOM 
Megakaryoblastic AML w/ t(1;22)(p13.3;q13.3); RBM15-MKL1, BCR-
ABL1 (provisional), NPM1, CEBPA (biallelic), RUNX1 (provisional) 
2. AML w/ myelodysplasia-related changes Dysplastic features in ≥50% of cells in two or more lineages 
3. Therapy-related myeloid neoplasms Earlier treatment with etoposide or alkylating agents 
4. AML, not otherwise specified AML with minimal differentiation, AML with or without maturation,  
Acute myelomonocytic leukemia,  
Acute monoblastic/monocytic leukemia, Pure erythroid leukemia,  
Acute megakaryoblastic leukemia, Acute basophilic leukemia,  
Acute panmyelosis with myelofibrosis   
5. Myeloid sarcoma Appearance of solid tumour made of myeloid blasts 
6. Myeloid proliferations of Down syndrome Transient abnormal myelopoiesis, 
Myeloid leukemia associated with Down syndrome 
FAB classification Morphology 
M0. Acute myeloid leukemia without differentiation 
M1. Acute myeloid leukemia with minimal differentiation 
M2. Acute myeloid leukemia with differentiation 
M3. Acute promyelocytic leukemia (hypergranular or typical) 
M4. Acute myelomonocytic leukemia 
M4v. Acute myelomonocytic leukemia with BM eosinophilia 
M5. Acute monocytic leukemia 
M6. Acute erythroid leukemia (Erythroleukemia) 
M7. Acute Megakaryoblastic leukemia 
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Prediction of patient’s risk and likelihood of survival has been an important part 
of medicine since the Book of Prognostics, written around 400 BC by Hippocrates. 
It is therefore of no surprise that the word prognosis derives from Greek words 
pro-, “before“ and gnôsis, “inquiry, investigation, knowing“. The foreknowledge 
of how different demographic, clinical and genetic factors identified at diagnosis 
affect outcome parameters is highly informative and impact treatment decisions. 
In AML, prognostic factors are roughly divided into patient-related and disease-
related factors with latter having the highest prognostic power. The patient-related 
factors include age, performance status, general health, and comorbidities, 
whereas disease-related prognostic factors consist of cytogenetic and molecular 
abnormalities (75). Currently only few factors influence treatment decisions and 
those that do, mainly tell clinicians whether patient is fit for intensive 
chemotherapy. Based on the most recent recommendations from the ELN expert 
panel, all patient-related factors beside age should be considered when deciding 
whether patient is fit to receive standard chemo-therapy regimen (63, 76).  
 
Fairly recent progress in the management of AML is the establishment of genetic 
risk groups, which provide solid background for risk stratification (77). The 
established risk groups (favorable, intermediate, and adverse) formulated by the 
National Comprehensive Cancer Network (NCCN) and ELN are based on 5-year 
OS rates, which in the three patient subsets are 55-65%, 24-41%, and 5-14%, 
respectively (78, 79). Both schemes are highly similar although some differences 
exist in the intermediate and adverse risk groups. Based on the NCCN version, 
patients with normal karyotype, trisomy 8, and those carrying c-KIT mutation 
with t(8;21), inv(16), or t(16;16) should be classified as intermediate-risk in 
addition to the factors listed on Table 3.  
 
Papaemmanuil et al recommended in 2016 that TP53, SRSF2, ASXL1, DNMT3A, 
and IDH2 should also be incorporated into the risk stratification groups since they 
are frequent mutated in AML and strong influencers of clinical outcome (5). Two 
of these mutations, namely TP53 and ASXL1, were recently added to the 2017 
ELN risk strafication scheme, however, the ELN panel thought there was 
insufficient evidence to warrant assignment of other mutated genes such as 
DNMT3A, IDH1, or IDH2 into the risk groups. On-going mutation profiling will 
continue to refine risk stratification and to facilitate identification of optimal 
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treatments for each patient. In the future, we may see the addition of IDH 
mutations in the risk groups as they are observed in roughly 20% of AML cases 
and strongly influence treatment decisions (4, 5). FDA has recently approved two 
IDH inhibitors (IDH2 inhibitor enasidenib and IDH1 inhibitor ivosidenib) for 
relapsed/refractory AML patients with IDH1 or IDH2 mutation (80, 81).  
 
Table 3. Prognostic risk stratification of AML (adapted from the ELN and the NCCN). 
Risk group 2017 ELN Criteria NCCN Guidelines Version 1.2018 
Favorable t(8;21)(q22;q22.1); RUNX1-RUNX1T1,  
inv(16)(p13.1;q22) or t(16;16)(p13.1;q22); CBFB-
MYH11,  
Mutated NPM1 without FLT3-ITD  
Mutated NPM1 with FLT3-ITDlow 
Isolated biallelic mutated CEBPA 
Core binding factor: inv(16) or t(16;16) or 
t(8;21), t(15;17), 
Mutated NPM1 without FLT3-ITD  
Mutated NPM1 with FLT3-ITDlow 
Isolated biallelic mutated CEBPA 
Intermediate Mutated NPM1 and FLT3-ITDhigh 
Wild-type NPM1 without FLT3-ITD or with FLT3-
ITDlow 
t(9;11)(p21.3;q23.3); MLL3-KMT2A,  
Cytogenetic aberrations not classified as favorable or 
adverse 
Core binding factor with KIT mutation 
Mutated NPM1 and FLT3-ITDhigh 
Wild-type NPM1 without FLT3-ITD or 
with FLT3-ITDlow (without poor risk 
genetic lesions) 
t(9;11)(p21.3;q23.3); MLL3-KMT2A  
Adverse t(6;9)(p23;q34.1); DEK-NUP214,  
t(v;11q23.3); KMT2A rearranged 
t(9;22)(q34.1;q11.2); BCR-ABL1 
inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, 
MECOM 
-5 or del(5q); -7; -17/abn(17p) 
Complex karyotype, monosomal karyotype 
Wild-type NPM1 and FLT3-ITDhigh 
Mutated RUNX1, Mutated ASXL1, Mutated TP53 
Complex karyotype, monosomal karyotype 
-5, 5q-, -7, 7q-, 11q23- non t(9;11),  
Inv (3), t(3;3), t(6;9), t(9;22),  
Normal cytogenetics: Mutated FLT3-ITD, 
Mutated TP53,  
Mutated RUNX1,  
Mutated ASXL1,  
Wild-type NPM1 and FLT3-ITDhigh 
 
Majority of fit patients receive standard induction treatment with cytosine 
arabinoside and an anthracycline (daunorubicin, idarubicin, mitoxantrone, or 
etoposide) at conventional or high dose. The standard upfront treatment termed 
7+3 (7 days of cytarabine at 100-200 mg/m2 and 3 days of daunorubicin at 60-90 
mg/m2, idarubicin at 12 mg/m2, or mitoxantrone 7 mg/m2) is administered 3-4 
times with a 4-6 week recovery between treatment blocks. Patients with adverse 
risk respond poorly to 7+3. The CR rates in fit patients under 60 years and in those 
60 or more, receiving 7+3 are 60-80% and 40-60%, respectively (82). Patients 
 
 
 
 
21 
with APL (10-15% of all AML cases) may be cured with all-trans-retinoic acid in 
combination with arsenic trioxide or chemotherapy, although some controversy 
exists regarding optimal dose and treatment schedule (83). Newly diagnosed t-
AML or AML patients with myelodysplasia-related changes (MRC) are eligible 
for CPX-351 (liposomal encapsulation of cytarabine and daunorubicin), which 
received FDA approval in 2017 and EMA approval in 2018. CPX-351 has resulted 
in longer OS compared to standard 7+3 treatment in patients with t-AML or AML-
MRC in randomized clinical studies (84).   
 
Few exceptions to the 7+3 regimen exist: approximately 30% of AML patients 
carrying FLT3-mutation are now eligible for treatment with 7+3 in combination 
with FLT3/multikinase inhibitor midostaurin (approved by FDA and EMA in 
2017) or gilteritinib (approved by the FDA in November 2018) (85). In younger 
newly diagnosed FLT3-positive AML patients, this induction therapy has led to 
significantly longer median survival compared to 7+3 alone (74.7 months versus 
25.6 months). The large trial that led to midostaurin approval lasted almost 10 
years and enrolled over 3000 patients (86). Another exception to 7+3 is that CD33-
positive AML patients are eligible for treatment with gemtuzumab ozogamicin 
(GO), an FDA- and EMA-approved antibody-drug conjugate targeted against 
CD33, in combination with cytarabine and daunorubicin. GO has been used in the 
treatment of core binding factor leukemia since the end of 2017 (87). Prevailing 
challenge with GO and similar compound (vadastuximab talirine) in clinical 
development is their association with veno-occlusive disease of the liver due to 
expression of CD33 by the hepatocytes (88).  
 
For intermediate and high-risk AML patients who fail to achieve CR after 7+3 
based induction therapy, allogeneic hematopoietic cell transplant (allo-HCT) is a 
potentially curative treatment option (89). Allo-HCT is also offered for selected 
patients with intermediate and adverse risk at first CR, but usually not for patients 
with favorable prognosis (90). Due to serious risks and side-effects, allo-HCT is 
generally not considered for older unfit AML patients as they have increased risk 
for treatment related mortality (91). 
 
Older unfit AML patients remain highly challenging to manage and presently lack 
standardized treatment options (92). The general consensus is that they should 
receive supportive care with or without low-dose chemotherapy or 
hypomethylating agents (78). Recent advancement is that they are now eligible 
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for venetoclax (BCL-2 inhibitor) or glasdegib (SMO inhibitor) treatment in 
combination with low-dose cytarabine, azacitidine, or decitabine. Both glasdegib 
and venetoclax were granted FDA approval in November 2018 (80, 93). CR rates 
(CR/CRi) in elderly treatment-naïve AML patients treated with venetoclax in 
combination with low-dose cytarabine or hypomethylating agent (decitabine, 
azacitidine) have been 54 – 73% (94, 95). Beyond targeted therapies described 
above, other actionable mutations in AML include KIT and BCR-ABL1. The 
selection of molecularly targeted therapies at diagnosis against these and other 
mutations requires faster screening methods as turnaround time for majority of 
commercial mutational profiles is currently too long (1- to 2-weeks).  
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The call for targeted therapies remains unanswered, considering that still roughly 
50% of AML patients below 60 years of age and up to 90% of those above 60 will 
relapse after achieving CR (96, 97). To meet the prevailing challenges, clinical 
trial pipelines have been loaded with novel biological therapies that have the 
potential to improve therapeutic success. As an example, two next-generation 
FLT3 inhibitors, namely crenolanib and quizartinib are currently in active phase 
III clinical trials. The ongoing phase III trials (NCT02668653 and NCT03258931) 
will show whether crenolanib or quizartinib are more efficient at inducing CR and 
lead to longer OS in combination with chemotherapy (in patients with FLT3-ITD 
or FLT3-TKD) compared to recently approved midostaurin or gilteritinib (98). In 
phase II trial of 29 newly diagnosed FLT3 mutated patients, crenolanib in 
combination with 7+3 and consolidation led to a highly promising CR rate of 72% 
after the first induction (99). Efficacy of FLT3 inhibitors in FLT3 mutated patients 
appears to be closely linked to mutational burden (100). It has been postulated that 
first-generation FLT3 inhibitors may be more beneficial at induction when 
mutational burden is low, while the more specific second generation FLT3 
inhibitors may have better clinical efficacy at relapse/refractory stage when the 
FLT3-ITD mutational burden is higher (101).  
 
Additional kinase inhibitors in phase III trials (active or recruiting) include SRC 
family kinase inhibitor dasatinib and PLK1 inhibitor volasertib, which are both 
evaluated with and without chemotherapy for AML. In the upcoming years, we 
may see the approval of additional IDH1 (BAY1436032) or IDH1/2 inhibitors 
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(AG-881) (102), epigenetic compounds such as HDAC inhibitor pracinostat, 
second-generation DNMT inhibitor guadecitabine, MDM2 antagonist idasanutlin, 
or targeted immunotherapies for patients with AML (103). In phase II trial of 50 
unfit older AML patients (NCT01912274), combination of pracinostat and 
azacitidine led to OS rates of 62% and 45% at one- and 2-year time-points, 
respectively. These percentages are notably better compared to single-agent 
azacitidine treatment in a similar patient cohort. At present, immune checkpoint 
inhibitors (nivolumab, pembrolizumab, durvalumab, atezolizumab, and 
ipilimumab), anti-CD123, anti-CLEC12A antibodies, bispecific T-cell engagers 
(blinatumomab), and chimeric antigen receptor T-cells against CD33 and 
CD123/CLL1 are also being assessed in clinical trials. Based on results from 
ongoing and past trials, it seems likely that more biologically targeted agents will 
enter clinics in combination with chemotherapy. Moreover, recent research has 
produced a vista, in which targeting leukemic stem cells in the up-front induction 
setting seems highly efficient treatment strategy (104).   
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Groundwork for personalized therapy of AML has been laid by improved 
awareness of genetic alterations and molecular heterogeneity. The first 
personalized therapy for AML was all-trans retinoic acid, which in combination 
with arsenic trioxide leads to permanent cures for most patients with retinoic acid 
receptor rearrangement (PML-RARA) (8). Since then, only few additional 
personalized therapies have been developed for AML including FLT3 and IDH1/2 
inhibitors against FLT3 and IDH mutations, respectively. Recently, BEAT AML 
initiative, which is the largest published work regarding the topic, discovered 
several associations between specific inhibitors and mutations (105). Specific 
findings were that ASXL1 mutated AML patients have high ex vivo sensitivity to 
HDAC inhibitor panobinostat, NRAS mutated patients to MAPK inhibitors, and 
FLT3/NPM1 mutated patients to BTK inhibitor ibrutinib. Moreover, 
BCOR/RUNX1 mutated patients had significant ex vivo sensitivity to JAK 
inhibitors and TP53 mutated patients to oxidative stress inducer elesclomol. Some 
of these associations and novel targeted agents will be tested in the upcoming and 
on-going clinical trials such as the BEAT AML® Master Trial.     
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Nucleoporin 98 (NUP98) gene encodes for a 98-kDa protein, which together with 
34 other membrane-bound proteins selectively passes macromolecules (proteins, 
RNA and ribosome subunits) through the nuclear pore complex (106). The first 
rearrangement involving NUP98 was discovered in 1996, when two groups 
simultaneously discovered t(7;11)(p15;p15.5)/NUP98-HOXA9 fusion gene in 
AML (107, 108). Subsequential work has identified at least 32 distinct NUP98 
rearrangements making it a second largest fusion gene network in AML (10). The 
number of detected NUP98 rearrangements has consistently increased throughout 
the past two decades. Apart from AML, NUP98 rearrangements have been 
detected from patients with MDS, CML in blast crisis, chronic myelomonocytic 
leukemia, juvenile myelomonocytic leukemia, acute lymphoblastic leukemia 
(ALL), bilineage/biphenotypic leukemia, and renal angiomyolipomas (109-113).  
 
The associated partner genes can roughly be divided to those with and without 
homeobox domains. Majority of the non-homeobox genes contain coiled-coils 
and few of them, namely AF10, PHF, JARID1A, NSD1, NSD3, and MLL, harbor 
plant homology domain fingers involved in chromatin recognition. In all NUP98 
rearrangements, N-terminal FG repeat containing portion of NUP98 is joined to 
C-terminal part of partner gene with fusion junctions usually located in introns 
between exons 11-12, 12-13, or 13-14 (109). The reciprocal NUP98 translocation 
products are intermittently found from AML patients with 5’-NUP98 fusion (114-
116). With the increasing number of known NUP98 rearrangements, it is 
transpiring that diverse hematological neoplasms may be associated with different 
NUP98 rearrangements. Therefore, it seems that partner gene may have an 
important role in determining which disease a patient develops (109). As an 
example, NUP98-SETBP1 and NUP98-IQCG fusion genes have only been 
detected from patients with T-ALL. Interestingly, while MDS is known to 
progress into AML, all of the NUP98 rearrangements detected in MDS have also 
been found from patients with AML (109). It currently remains unclear whether 
specific cell types are more prone to particular NUP98 translocation events than 
others. Another interesting aspect is that roughly 25% of NUP98 rearrangements 
are detected from therapy-related AML patients. This observation implies that 
exposure to conventional cancer therapies may increase the prevalence of 
particular NUP98 rearrangements such as NUP98-TOP1, NUP98-DDX10, 
NUP98-PRRX1, or NUP98-PRRX2 (117). Recently, NUP98-translocation was 
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found from a woman with bilateral renal angiomyolipomas and from her healthy 
three-year old daughter (113). This finding suggests that NUP98-translocations 
are early leukemogenic events that may occasionally occur in the germline. 
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The t(5;11)(q35;p15.4) translocation, which joins NUP98 and NSD1 genes 
together, was initially discovered by Jaju et al in 1999 from three pediatric AML 
patients with chromosome 11-specific subtelomeric FISH probes (118). The 
probes captured a reciprocal trade of genetic material between 5q and 11p 
subtelomeric regions corresponding to NUP98 and NSD1. Within NUP98, the 
precise breakpoint was shown to localize in intron between NUP98 exons 12 and 
13 (119). Two later studies confirmed that NUP98-NSD1 fusion results from 
insertion of 5’NUP98 fraction into the NSD1-3’ locus. Subsequent work has 
validated that the t(5;11)(q35;p15.4) translocation is a recurrent event in AML 
(116, 120, 121). These patients are predominantly CN-AML (78%) with high 
WBC counts, particularly if FLT3-ITD positive, and predominantly have FAB-
M4/M5 morphology (116). Ostensibly, NUP98-NSD1 has also been detected from 
sporadic cases with MDS and acute biphenotypic leukemia (11, 117).  
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To uncover the clinical relevance of NUP98-NSD1 in AML, several studies have 
assessed its prevalence. In United Kingdom, prevalence of NUP98-NSD1 in 
pediatric AML (< 19 years) was 7% (4/54) (122), while in Portuguese and 
Japanese cohorts the reported percentages have been 5% (1/20) (123) and 4.8% 
(6/124) (124), respectively. In a combined cohort of 293 pediatric AMLs collected 
from three study groups (the Dutch Childhood Oncology group, the AML-
Berliner-Frankfurt-Münster study group, and the Saint-Louis Children’s 
Hospital), NUP98-NSD1 was identified from 4.4% (13/293) of cases. The latter 
study also found that in pediatric CN-AML, NUP98-NSD1 is present in 16.1% 
(10/62) of the cases (Figure 3) (116). In Children’s Oncology Group (COG) trial 
patients in the United States, NUP98-NSD1 was found from 5% (32/683) (120). 
On the contrary, in Austrian and French pediatric AML cohorts, NUP98-NSD1 
frequencies have been 2% (1/59) (125) and 3% (17/574), respectively (126).  
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In adult AML, NUP98-NSD1 is a relatively rare event with a reported prevalence 
of 1.3-3%. In a combined analysis of German AML SHG 0295 and SHG 0199 
trial patients (< 60 years), NUP98-NSD1 was detected from 1.4% (7/504) (121). 
In another German cohort, NUP98-NSD1 was found from 2.1% (8/378) of adult 
CN-AML patients (127). Consistently, the frequency of NUP98-NSD1 in the 
collective Dutch-German-French AML cohort was 1.3% (10/788) in adults and 
2.3% (8/344) in adult CN-AML (116). Furthermore, in the South West Oncology 
Group trial cohort in the United States, the prevalence of NUP98-NSD1 in adult 
AML was 3% (7/237) (120), while it was 1.5% (3/200) in the TCGA (The Cancer 
Genome Atlas) cohort of 200 adult de novo AML patients (4). In Canada, NUP98-
NSD1 was identified from 1.7% of adult AML patients (7/415) (128).  
 
 
Figure 3 Frequency of NUP98-NSD1 in pediatric and adult CN-AML. Adapted from 
Hollink et al, Blood, 2012 (116).   
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As yet, only limited number of studies have investigated how NUP98-NSD1 
fusion may promote leukemic transformation and whether additional mutations 
are needed for triggering leukemogenesis. Currently, it is known that NUP98-
NSD1-driven transformation is closely linked to aberrant gene expression and that 
NUP98-NSD1 exerts its leukemic functions in the nucleus where it forms nuclear 
speckles (116, 129, 130). The precise mechanisms of how NUP98-NSD1 mediates 
expression changes remain poorly understood. It seems apparent that the N-
terminal portion of NUP98 plays a central role as it is involved in more than 30 
unique NUP98 translocations (109, 111, 112).    
 
Pediatric CN-AML (n = 62)
16%  NUP98-NSD1
24%  NPM1
13%  CEBPAdm5%  MLL-PTD
unknown 42%
Adult CN-AML (n = 344)
2%  NUP98-NSD1
56%  NPM1
unknown 42%
MLL-PTD (NA)
CEBPAdm (NA)
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In a benchmark work, Wang and colleagues presented that sub-lethally irradiated 
syngeneic BALB/c mice develop AML after being injected with retrovirally 
transduced Lin- progenitors expressing NUP98-NSD1 (129). They discovered that 
NUP98-NSD1 halts the differentiation of Lin- marrow derived progenitors by 
enforcing cellular self-renewal and by binding next to HoxA7 and HoxA9 genomic 
loci. They pointed out that at this loci, NUP98-NSD1 activates and maintains the 
expression of several Hox-A genes and Meis1 by colocalizing CBP/p300 mediated 
H3/H4 acetylation and H3mK36 of regulatory elements. They concluded that 
these events disallow EZH2 binding in proximity to HoxA9 and appearance of 
H3mK27, which has a critical role in silencing of HoxA genes.  
 
The evidence suggesting that NUP98-NSD1 alone induces AML, however, could 
not be reproduced by Thanasopoulou et al. By transplanting NUP98-NSD1 
transduced Lin- marrow progenitor cells (harvested from methylcellulose 
cultures) into sub-lethally irradiated syngeneic BALB/c mice, they found that 
NUP98-NSD1 alone induces a phenotype resembling myeloid hyperplasia (120). 
On the contrary, they observed that all mice injected with Lin- marrow cells co-
expressing NUP98-NSD1 and FLT3-ITD rapidly develop AML. It is therefore 
likely that NUP98-NSD1 induces a premalignant phenotype in the HSCs en route 
to full-blown malignancy upon acquisition of additional cooperative mutations 
such as FLT3-ITD and WT1 that facilitate complementary effects on cell 
phenotype. 
 
Recent work has provided additional insights into the leukemogenic mechanisms  
by reporting that NUP98-NSD1 may be recruited to chromatin adjacent to HOXA-
B cluster genes and Meis1 by several mechanisms including interactions with 
MLL1 (131), Crm1 (132), or Wdr82 and the WSC complex (Wdr82 – 
Set1A/COMPASS) (133). The above-cited study by Franks et al discovered that 
NUP98-NSD1 promotes aberrant H3K4me3 at its binding sites and thereby drives 
constitutive up-regulation of various developmental genes linked to AML. 
Another line of evidence suggests that DOT1L-AF10 complex mediates higher 
degree of H3K79 methylation and thereby cause constitutive activation of HOX 
cluster genes in NUP98-NSD1+ cells (134). Additional clues to leukemogenic 
mechanisms may be provided by coiled-coil regions of NUP98-NSD1 that enable 
interactions with multiprotein complexes or other transcription factors (135). 
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Roughly 26% (11/42) of NUP98-NSD1+ AML patients have comutated FLT3-
ITD and WT1, whereas either FLT3-ITD or WT1 mutation is found from 70- 91% 
and 29-50% of the cases, respectively (116, 120, 127, 128). Interestingly, NUP98-
NSD1+/FLT3-ITD+ AML patients have also been found with concurrent MYC 
mutations (128) and NUP98-NSD1+/WT1+ AML patient with concurrent N-RAS 
mutation (116). It seems apparent that NUP98-NSD1+ patients rarely harbour less 
than three genomic alterations. The list of other infrequently detected comutations 
include ASXL1, CEBPA, KIT, and K-RAS (4, 116, 121, 124, 126, 128, 136-138). 
Although NUP98-NSD1 is predominantly reported as a sole cytogenetic 
abnormality, many co-existing cytogenetic aberrations have been reported 
including del 3q, del 5q, del 9q, del 11p, +6, +8, +13, +21, +22, 
t(10;19)(q23;q13.4), t(12;15)(p13;q25), an inv (3)(q21q26) karyotype with 
monosomy 7 (116, 118, 121, 122, 124, 139-141). Further studies are warranted to 
learn how the various co-mutations or cytogenetic co-alterations may affect 
therapy responses and patient survival in this biologically distinct subgroup of 
AML. 
 
Until now, only few studies have explored gene expression changes in NUP98-
NSD1+ AML patients. Two studies have applied RNA-Seq (128, 142) and three 
studies microarray analysis with HGU 133 Plus 2.0 array (116, 124) or GeneChip 
Mouse Genome 430 2.0 array (129). In mouse progenitors transduced with 
NUP98-NSD1, six genes, namely HoxA5, HoxA7, HoxA9, HoxA10, Meis1, and 
Rab38 were shown to be up-regulated 5-fold or more (129). Analyses using 
NUP98-NSD1+ patient samples have confirmed significant overexpression of 
several HOX-AB cluster genes. 
 
According to two microarray analyses, the number of differentially expressed 
probe sets in NUP98-NSD1+ AML patients is lower compared to other AMLs 
(116, 124). In the microarray analyses, only 15 probe sets were significantly up-
regulated in both data sets in addition to HOX cluster genes. The most highly up-
regulated genes included NKX2-3, VENTX, NRG4, FLJ42875, LOC404266, 
H2AFY2, TRGCA, CPNE8, CDCP1, and PRDM16. Recent work by Shiba et al 
has validated PRDM16 overexpression in a Japanese cohort of NUP98-NSD1+ 
AML patients (n = 11) (143). RNA-Seq based expression analysis by Lavallée et 
al was highly consistent with the two microarray analyses. Interestingly, NKX2-
3, VENTX, FLJ42875, CDCP1, H2AFY2, NRG4, CPNE8, and PRDM16 were 
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shown to be among the 100 most up-regulated genes in NUP98-NSD1+ AML 
compared to non-NUP98-NSD1 AML cohort. RNA-Seq data from another study 
showed that expression profile of NUP98-NSD1+ patient samples is retained in the 
xenografts (142). Pathological relevance of the identified comutations and 
associated transcriptome changes remain largely unstudied.  
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Already two decades ago when the first three NUP98-NSD1+ children were 
identified, it was surmised that this patient subgroup has poor response to 
induction chemotherapy and short OS ranging from 10 to 18 months (118). 
Following the initial observations, aggressive clinical course with a high relapse 
rate has been shown to be a defining feature of NUP98-NSD1+ AML patients and 
has been correlated with increasing NUP98-NSD1 expression (116, 122). 
Although analysed patient cohorts have been relatively small, the reported 3-4-
year event-free survival (ranging from 0-33.3%) and OS rates strongly suggest 
that conventional chemotherapeutic regimen rarely leads to permanent cures free 
of complications in patients with NUP98-NSD1 (116, 120, 124, 137). According 
to Fasan et al, the median event-free survival in adult patients with NUP98-NSD1+ 
(n = 6) is 1.8 months compared to 11 months in NUP98-NSD1- cohort (n = 251) 
(127). Another study provided realworld data suggesting that pediatric patients 
with NUP98-NSD1 respond better to first-line treatments than adults. The 4-year 
OS in a pediatric cohort was shown to be 31%, while it was 11% in adults (116). 
Similar OS percentages in NUP98-NSD1+ pediatric cohorts have been reported by 
at least two other studies (120, 124).  
 
Majority of AML patients with NUP98-NSD1 and concurrent FLT3-ITD never 
reach CR (144). In a multi-center trial cohort reported by Ostronoff et al, only 
28% (9/32) of pediatric AML patients (COG trial cohort) and 20% (1/5) of adults 
(South West Oncology Group FLT3-ITD cohort) with concomitant NUP98-NSD1 
and FLT3-ITD achieved CR. The lowest CR rate (9%) was seen in NUP98-NSD1+ 
AML patients with concurrent FLT3-ITD and WT1 mutations (1/11) (120). In line 
with these findings, a recently published paper, which included nearly 1000 
patients showed that FLT3-ITD yields markedly inferior outcomes in combination 
with WT1 mutations and/or NUP98-NSD1 compared to patients harboring FLT3-
ITDs alone or in combination with mutated NPM1 (145).  
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The overall objective of this study was to provide insights into the biology and 
treatment of AML patients with high-risk NUP98-NSD1 and concomitant FLT3-
ITD. These patients urgently need for more effective and less toxic treatments as 
majority of them are unresponsive to standard induction chemotherapy.   
 
 
The specific aims of this study were: 
 
I.  To facilitate the molecular monitoring of NUP98-NSD1 fusion 
 gene in AML by studying alternative splice variants. 
 
II.  To discover novel candidate drugs and drug combinations for 
 the treatment of AML patients with NUP98-NSD1 fusion and 
 concomitant FLT3-ITD. 
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The patient material consisted of BM aspirates and skin biopsies from patients and 
healthy donors who had signed written informed consent before sampling. 
Mononuclear cells (MNCs) were isolated from BM aspirates using Ficoll-Paque 
Premium™ density gradient centrifugation according to manufacturer’s protocol 
(GE Healthcare, Little Chalfont, UK). All samples were collected in accordance 
with the updated tenets of the Declaration of Helsinki and with written informed 
consent. Ethical permits for the study were acquired from the Helsinki University 
Hospital Ethics Committee (permit numbers 239/13/03/00/2010 and 
303/13/03/01/2011). 
 
In study I, chimeric NUP98-NSD1 transcripts and alternative splicing events were 
studied from three t(5;11) translocation positive AML patients (600, 3600, and 
3660) (Table 4). The control group consisted of four males and six females 
without t(5;11) translocation. The mean age of the patients and controls at the time 
of sampling was 46 years (range 32–59.2) and 42.6 years (range 20.4 – 72.2), 
respectively. The control samples (N = 19) included healthy individuals and 
patients with AML, MDS, ALL, chronic myelomonocytic leukemia, and CML. 
RNA sequencing data was analyzed from samples collected at diagnosis (N = 2), 
relapse (N = 10), refractory stage (N = 6), and remission (N = 1).  
 
In study II, DSRT was performed to BM MNCs from four NUP98-NSD1+/FLT3-
ITD+ AML patients (Table 4), nine NUP98-NSD1 negative AML patients with 
FLT3-ITD, and ten healthy donors. The median age of NUP98-NSD1+ patients at 
the time of sampling was 54.8 (range 39.8–59.2), while the median age of controls 
(five males and four females) was 59.8 years (range 27.7–77.8). RNA-seq was 
performed in parallel to three NUP98-NSD1+/FLT3-ITD+ AML patients, nine 
NUP98-NSD1 negative AML patients with FLT3-ITD and BM CD34+ cells from 
four healthy donors. CD34+ cells were enriched from the healthy donor BM 
MNCs using EasySep® Human CD34+ Selection Kit (StemCell Technologies, 
Vancouver, Canada). Exome sequencing was carried out to two NUP98-
NSD1+/FLT3-ITD+ AML patients and phosphor-kinase antibody array (R&D 
systems, Minneapolis, MN, USA) to one NUP98-NSD1+/FLT3-ITD+ patient.  
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Table 4. Clinical and demographic characteristics of the NUP98-NSD1+/FLT3-ITD+ 
study patients at the time of sampling.  
Characteristics 600_2 3600_1 3660_3 7499_2 
Gender Male Female Male Female 
Age at diagnosis 54 39 58 32 
WHO classification Acute monocytic 
leukemia 
Acute myeloblastic 
leukemia with 
maturation 
Acute monocytic 
leukemia 
Acute myeloblastic 
leukemia with 
maturation 
FAB subtype M5b M2 M5 M2 
BM blast count 75 40 95 70 
Karyotype 46 XY, del 3q, t(12;15) 
t(5;11)(q35;p15.4) 
46 XX, 
t(5;11)(q35;p15.4) 
46 XY, del (9)(q21-22) 
t(5;11)(q35;p15.4) 
46, XX, 
t(5;11)(q35;p15.4) 
FLT3-ITD size (bp) 57  213 57 51 (ITD#1) 
57 (ITD#2) 
FLT3-ITD allelic ratio 
(heigh fraction) 
0.17 0.28 0.40 0.40 
BM immunophenotype CD33+, CD38+, CD4+, 
CD13+, CD11b+, 
HLA-DR+, CD65+, 
CD14+, CD64+, CD15; 
a proportion of cells 
CD177+ 
CD34+, CD33+, CD3-, 
CD135+, (weak 24%), 
TdT+ (28%), CD36+, 
CD38+, CD13+, MPO+ 
, CD11b+, HLA-DR+, 
CD117+, CD15+, 
CD65+, CD79- 
CD38+, CD34+, CD9-, 
CD33+, CD13+ weak 
(16%), CD16-, MPO+, 
CD11b+ (26%), HLA-
DR+, CD19-, cyCD3-, 
NG2-, CD14-, CD25+, 
cyCD79a-, CD117+, 
CD56-, CD2+ (26%), 
CD203c, CD15+ (21%) 
CD42a&61-, CD123+, 
CD105+, IREM2-, 
CD4+ weak (36%), 
CD64-, CD71+, CD7-, 
CD36+, CD133-, TdT+,  
CD41a, CD42b-,CD22+ 
, CD135+ weak, CD96+ 
weak (66%) 
CD34+ (48%), CD33+, 
CD117+, HLA-DR+, 
MPO+, CD19-, CD7+, 
CD4-, CD3-, CD13- 
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Total RNA (1 μg) from index patient’s BM MNCs was reverse transcribed to 
cDNA using SuperScript™ III First-Strand Synthesis System for reverse 
transcription PCR with Oligo (dT) primers (Thermo Fisher Scientific). NUP98-
NSD1 was amplified from cDNA using primers 297/298 (Table 2) with Phusion™ 
(HF) DNA polymerase (Thermo Fisher Scientific). PCR protocol was as follows: 
95°C for 2 min, 35 cycles of denaturation at 95°C for 20 s, annealing at 54°C for 
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10 s, and elongation at 72°C for 100 s with a final extension at 72°C for 5 minutes. 
Amplified fragments were separated on 1% agarose gel electrophoresis with 
SYBR® Safe DNA stain (Thermo Fisher Scientific) and extracted using 
NucleoSpin® Gel and PCR Clean-up Kit (Macherey-Nagel, Duren, Germany). 
Fragments corresponding to NUP98-NSD1 were ligated into pCR® 2.1-TOPO® 
vectors using TOPO™ TA Cloning™ Kit and transformed into One Shot™ 
TOP10 Chemically Competent E. coli based on manufacturer’s protocol (Thermo 
Fisher Scientific). After overnight incubation at +37°C, NUP98-NSD1+ colonies 
were identified from LB + ampicillin (100 μg/ml) agar plates with colony-PCR. 
Positive colonies were cultivated overnight at +37°C. Next day, plasmids were 
extracted with NucleoSpin® Plasmid Easy Pure Kit (Macherey-Nagel) and 
Sanger sequenced bidirectionally (with primers described on Table 5) using 
ABI370xl DNA Analyzer and BigDye Terminator v3.1 Cycle Sequencing Kit 
(Applied Biosystems, South San Francisco, CA, USA). Nucleotides were called 
using Sequencing Analysis v5.2 software and trace files analyzed in 
Sequencher™5.2 (Gene Codes Corporation, Ann Arbor, MI, USA). Nucleotide 
sequences were aligned against NCBI (National Center for Biotechnology 
Information) reference sequences (NM 139131.3 and NM 022455.4) to assemble 
full-length NUP98-NSD1 sequences. 
 
In study II, NUP98-NSD1 transcripts were subcloned from pCR® 2.1-TOPO® 
vectors into pLeGO-iCER2 lentiviral expression vectors. Briefly, NUP98-NSD1 
fusions were amplified with Phusion™ HF DNA polymerase using primers 
297/298. PCR products were purified by mixing twith 3 M NaAc (2μl) and 99% 
EtOH (60 μl). The mixture was centrifuged at 14,000 rpm for 5 minutes and 
supernatant discarded. The pellets were washed twice with 70% ethanol and dried 
for 5 minutes at 70°C before exposing them to T4 polynucleotide kinase (10U/μl) 
following manufacturer’s protocol (Thermo Fisher Scientific). The pLeGO-
iCER2 vector was digested with Stu I restriction enzyme (10U) (New England 
Biolabs, Ipswich, MA, USA). T4 PNK treated insert cDNA and Stu I digested 
plasmid were resolved on 1% agarose gel and extracted using Nucleospin® Gel 
and PCR Clean-up Kit (Macherey-Nagel, Duren, Germany). The plasmid DNA 
was treated with FastAP Thermosensitive alkaline phosphatase (Thermo Fisher 
Scientific). Overnight ligations were performed using T4 DNA Ligase (New 
England Biolabs). Stbl3 Chemically Competent E. coli cells were heat-shock 
transformed with ligated expression vectors and plated on LB+ampicillin (100 
μg/ml) agar plates for overnight incubation at +37°C. Positive clones were 
 
 
 
 
34 
identified with colony-PCR. Plasmid extractions and Sanger sequencing was 
performed to identify clones with NUP98-NSD1 transcripts in correct orientation.    
 
Table 5. Oligonucleotide primers applied for PCR and capillary sequencing.  
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Lentiviral packaging of pLeGO-iCER2 (Addgene No. 27346), pLeGO-iCER2-
NUP98-NSD1 expression vectors was done in HEK293T cells. Briefly, an hour 
before transfection DMEM (Lonza, Basel, Switzerland) complete (10% fetal 
bovine serum, 1% Penicillin-Streptomycin, 1% L-glutamine) was replaced with 9 
ml of Gibco™ OPTI-MEM I™ (Thermo Fisher Scientific). Expression vector 
pLeGO-iCER2 (10 µg), pCMV, dr8.74 (5.3 µg) (Addgene No. 22036) and 
pCMV-VSV-G (3 µg) (Addgene No. 8454) were co-transduced into 70-80% 
confluent HEK293T cells using FuGENE® HD reagent following manufacturer’s 
protocol (Promega, Fitchburg, WI). After overnight incubation at +37°C, OPTI-
MEM I™ was replaced with DMEM complete. Viral supernatants were collected 
twice during 48-hours and filtered with 0,45 µm syringe filter (Sarstedt, 
Nümbrecht, Germany) into 100,000 MWCO Vivaspin 20 columns (Sartorius, 
Hamburg, Germany). Viral particles were concentrated (20X) by centrifugation 
Primer Primer name Sequence (5’->3’) GC (%) Tm (°C) 
24 M13F GTAAAACGACGGCCAGT 52.9 58.7 
25 M13R CAGGAAACAGCTATGAC 47.1 50.7 
82 AML.600_cDNA_-F AGCCTTTGGGGCCCCTGGATTTA 56.5 74.2 
83 AML.600_cDNA_-R CCAAAAGCCACTTGCTTGGCTTCC 54.2 73.7 
297 NUP98-NSD1-FL-F ATGTTTAACAAATCATTTGG 25.0 54.0 
298 NUP98-NSD1-FL-R CTACTTCTGTTCTGATTCTG 40.0 51.2 
307 seq_NSD1-R2 TTAACATGCTCATGATTTCGG 38.1 62.4 
308 seq_NSD1-F2 CTGTGTCCGCTGTCCTGTGG 65.0 69.5 
309 seq_NSD1-R3 TTCTTGCAGGAGACGAGC 55.6 62.0 
310 seq_NSD1-F3 AGGCCAAAGAATCAACCC 50.0 61.5 
311 seq_NSD1-R4 CCTGGGGTCTGCTCAGC 70.6 65.0 
312 seq_NSD1-F4 AGCAAAGGTCTGGGGCATAT 50.0 64.5 
400 NSD1-seq-B TCCTTGGTTTCCAGCCAGAG 55.0 66.5 
401 NSD1-seq-A CTGGCCTGGGTGAGTGATTT 55.0 66.3 
402 NUP98-NSD1-C TTGGCACAAATACCAGTGGG 50.0 65.6 
403 NUP98-NSD1-D CGGGATCGTGTTCTACACCT 55.0 63.9 
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in KUBOTA 7780 High Speed Refridgerated Centrifuge (KUBOTA, Osaka, 
Japan) at +4°C for 60 minutes at 3000 rpm. Ba/F3 and 32D cells were transduced 
with lentiviruses (carrying either empty pLeGO-iCER2 or pLeGO-iCER2-
NUP98-NSD1) on 6-well tissue culture treated plates by adding 0.5 ml of fresh or 
cryopreserved viral concentrate on 200,000 cells in the presence of polybrene (0.8 
µg/ml). Transduced cells were expanded in RPMI 1640 complete medium 
supplemented with mouse IL-3 (10ng/ml). Presence of replication competent 
virus was excluded 10-14 days later at functional genomics unit.  
 
Retroviral packaging was done in HEK293T Lx cells. Expression vectors were 
mixed with third generation packaging plasmid in 2:1 molecular ratio. DNA 
complexes were formed by mixing plasmids with 25 µl TurboFect (Thermo Fisher 
Scientific) and serum free medium (1 ml). Mixture was incubated at room 
temperature for 20 minutes and added on HEK293T Lx cells. After overnight 
incubation at +37°C, medium was changed to DMEM complete. 24 hours later, 
viral supernatants were collected and filtered into Vivaspin 20 columns 
(Sartorius). Viruses were concentrated by centrifuging for 45 minutes at 3000 
rpm. Viruses were snap-frosen in liquid nitrogen and stored at -80°C until use.  
 
BM cells were isolated from bones of BALB/c mice. Cells were filtered and 
treated with red blood cell lysis buffer for 10 minutes on ice. Lineage depletion of 
the BM cells was done using Mouse Cell Lineage depletion kit (R&D systems, 
Minneapolis, MN, USA). BALB/c Lin- cells were transduced on 6-well plates by 
adding retrovirus (1 ml) to 2ml medium with cells (500,000 cells/well) in the 
presence of polybrene (2 µg/ml). The plates were sealed with parafilm and spinned 
for 90 min at 2500 rpm. After 3-hour recovery in incubator, cells were washed 
with 1xPBS and placed in RPMI complete medium supplemented with mIL-3 (6 
ng/ml), IL-6 (10 ng/ml), and mSCF (10 ng/ml). NUP98-NSD1+ cell selection was 
done by incubating the cells with 0.8 mg/ml neomycin (Gibco Geneticin G418 
sulfate) for 9-14 days as described (146).   
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Lentivirally transduced Ba/F3 and 32D cells expressing NUP98-NSD1 or empty 
plasmid vector were sorted by fluorescence activated cell sorting using BD Aria 
IIu (BD, Franklin Lakes, NJ, USA) high-speed cell sorter based on cerulean 
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fluorescence protein (CFP) expression. CFP was excited with 405 nm laser and 
emission captured with 530/30 bandpass filter. Doublets were excluded based on 
the forward scatter (FSC-A/FSC-H). CFP positive cells were sorted into 15ml 
tubes and expanded for further analysis. Green fluorescent protein (GFP) positive 
BALB/c cells, transduced with pMSCV-IRES-GFP or pMSCV-FLT3-ITD-IRES-
EGFP containing retroviruses, were sorted with BD Influx.  
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Drug sensitivity and resistance testing (DSRT) measures how sensitive or resistant 
different cells are to various compounds. In this thesis, cell viability-based high-
throughput DSRT assay was performed to primary patient cells and experimental 
cell lines using up to 306 anti-cancer drugs targeting wide range of molecular 
targets. Drugs were acquired from commercial sources as described in study II 
and consisted of FDA, PMDA, and EMA approved drugs (45%), investigational 
compounds (33%), and probes (22%). Briefly, drugs were reformatted on tissue 
culture treated 384-well flat clear bottom white polystyrene microplates (Corning, 
New York, NY, USA) in five to eight concentrations over a 10,000-fold 
concentration range (e.g. 0,1-1,000 nM) using an Echo 550 acoustic dispenser 
(Labcyte Inc, Sunnyvale, CA, USA). The water-soluble compounds were diluted 
in water and other compounds in dipolar aprotic solvent (100% dimethyl 
sulfoxide). To ensure compound activity, drug plates were held in pressurized 
StoragePods® (Roylan Developments Ltd., Fetcham, UK) under inert nitrogen 
gas until use or a maximum of four weeks from plate preparation. 
 
Cells were counted using CountessTM automated cell counter (Thermo Fisher 
Scientific) and dispensed on assay plates at a concentration of 1,500 to 10,000 
cells in 20 µl. Prior to adding cells, drugs were solubilized in 5 µl of culture 
medium. Assay plates were centrifuged after each liquid handling step to place 
liquids on the bottom of each well and agitated with Titramax 1000 platform 
shaker (Heidolph, Schwabach, Germany) at 450 rpm for 5 min. For pilot 
combinatorial screens, dasatinib was added on the wells within 5 µl of priming 
solution at 500 nM (final concentration 100 nM/25 µl). All liquid handling steps 
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were done with a peristaltic Multidrop™ Combi Reagent Dispenser (Thermo 
Fisher Scientific). After each assay set-up, drug plates were incubated in a 
humidified incubator at +37°C for 72 hours. Cell viabilities were measured with 
CellTiter-Glo® reagent (25 µl/well) according to manufacturer’s protocol 
(Promega, Madison, WI, USA). Luminescence from each well was quantified 
with PHERAstar® FS microplate reader (BMG Labtech, Offenburg, Germany). 
Luminescence data was normalized to positive (100 µmol/L benzethonium 
chloride) and negative (100% dimethyl sulfoxide) control wells to generate dose-
response curves for each drug based on normalized cell survival. The data quality 
was assessed with a Z-prime statistic (147). Curves were fitted in Dotmatics 
Browser v4.8 (Dotmatics Ltd., Herts, UK) or in Breeze (in-house platform) using 
a four parametric logistic fit function that considers slope of the curve, top and 
bottom asymptote, and inflection point. Outliers were excluded manually. 
Subsequently, drug sensitivity score (DSS) was calculated for each drug from area 
under the curve beween 10% and 100% inhibition (relative to the total area) by 
applying previously described mathematical algorithms (148, 149). Patient-
specificity of the drugs was assessed using a selective DSS (sDSS), which 
indicates the difference in DSS between median of healthy controls and DSS of 
each patient sample. Likewise, drug specificities in cell lines were evaluated by 
subtracting DSS of mock-transduced cells from transduced cell lines. Synergy 
scores (δ) for various drug combinations were calculated in SynergyFinder using 
a zero-interaction policy method (150, 151).   
 
Drug responses were initially compared between NUP98-NSD1+/FLT3-ITD+ BM 
MNCs from four AML patients and healthy donor BM MNCs to identify hits. The 
hits were further evaluated in the context of NUP98-NSD1-/FLT3-ITD+ AML 
patients to discover potential candidate compounds. In vitro proof-of-efficacy 
studies were carried out using experimental cell lines. Selective responses were 
assessed for each drug class to capture significant differences in sensitivities 
between cells expressing NUP98-NSD1 and FLT3-ITD alone or in combination.  
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Total RNA was extracted from BM MNCs and BM CD34+ cells using RNeasy 
Mini Kit (Qiagen, Hilden, Germany) or Total RNA Purification Kit (Norgen 
Biotek, Thorold, Canada). RNA integrity numbers were assessed using 2100 
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Bioanalyzer with RNA Nano or Pico chips (Agilent Technologies, Santa Clara, 
CA, USA). Ribo-Zero rRNA Removal Kit (Epicentre, Madison, WI, USA) was 
used for removing ribosomal RNAs from RNA samples. Next, RNA was purified 
with RNeasy® MinElute® Cleanup Kit (Qiagen) and reverse transcribed into 
double stranded cDNA with Superscript® Double-Stranded cDNA Synthesis Kit 
(Thermo Fisher Scientific) with random hexamers (New England Biolabs). 
Sequencing libraries were bar-coded with Nextera (Epicentre) or ScriptSeq 
technologies (Illumina, San Diego, CA, USA) and enriched with ligation PCR 
according to manufacturer’s protocol (Illumina). After size selection (350-700 bp) 
from agarose gel (2%), fragments were column purified with QIAquick gel 
extraction kit (Qiagen) and sequenced with Illumina HiSeq™2000 or 
HiSeq™2500.  
 
In study I, the average length of paired FASTQ reads was 317 nucleotides per 
mate (range, 104-530 bp). Reads were initially aligned against human reference 
(GRCh38) using TopHat v2.0.3 and extracted using Perl scripts (152). Extracted 
reads were executed in FusionCatcher and inspected in integrative genomics 
viewer to detect NUP98-NSD1 supporting reads (153, 154). To overcome 
detection, quantification, and visualization limits, an artificial FASTA format 
NUP98-NSD1 reference sequence was created. Therefore, NUP98 (NM 
139131.3) and NSD1 (NM 022455.4) sequences were extracted from PubMed 
(NCBI database) and annotated using a general feature format annotation file, 
which was necessary to create for aligning FASTQ reads with artificial fusion 
correctly. Aligned reads were extracted and processed by removing PCR 
duplicates, non-primary reads, and reads with low mapping quality (< 10). Final 
read counts were acquired using SAMtools (155).  
 
In study II, FASTQ reads were aligned against human (GRCh38) or mouse 
(BALB/c) reference genome using STAR aligner (gap-aware) together with 
EnsEMBL reference gene models (Ensembl v82) (156). The normalization of 
unprocessed FASTQ reads was done using trimmed mean of M values method. 
The log2 CPM values were calculated using EdgeR R package (3.18.1.) (157). 
The normalized log2 CPM values of specific drug target genes were compared 
between NUP98-NSD1+/FLT3-ITD+ AML patients, healthy donor BM CD34+ 
cells, and NUP98-NSD1-/FLT3-ITD+ AML patients. Similar comparisons were 
made with experimental BALB/c cells. Unsupervised hierarchical clustering of 
mean centered HOX AB-cluster gene expression (log2 CPM) in different samples 
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was done based on euclidean distance using complete linkage method. The 
heatmaps were generated using R package pheatmap (1.0.8.). 
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For array comparative genomic hybridization (A-CGH), three micrograms of 
genomic DNA from index AML patient was digested and labelled as previously 
described (158). Genomic DNA was extracted from the BM MNCs with DNeasy 
Blood & Tissue Kit or QIAamp DNA Mini Kit (Qiagen). The processed DNA was 
hybridized to Human CGH (244K) Microarrays (Agilent Technologies) 
containing up to 1x106 60-mer oligonucleotide probes according to standard 
procedure from the manufacturer. Copy number variations were analysed with 
Genomic Workbench software version 5.0 (Agilent Technologies).  
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Exome sequencing was performed to 1-3 µg of genomic DNA isolated from 
patient 600 and 3660 using DNeasy Blood and Tissue Kit or AllPrep DNA/RNA/ 
Protein Mini Kit (Qiagen). Exomes were captured and sequenced with NimbleGen 
SeqCap EZ v2 capture kit (Roche NimbleGen, Madison, WI, USA) using an 
Illumina HiSeq™ 2500 instrument. The bioinformatic pipeline for mutation 
calling, annotation and data analysis has been previously described (149, 159).  
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The FLT3-ITD allelic burden and ITD lengths in NUP98-NSD1+/FLT3-ITD+ 
AML patients were assed using fragment analysis. Briefly, FLT3-ITD region from 
each patient was amplified using 10ng of genomic DNA with PCR primers: 5’-
6FAM GCAATTTAGGTATGAAAGCCAGC-3’ and 5’-CTTTCAGCATTTTG 
ACGGCAACC-3’ as previously described (160). PCR products were diluted 
1:100 and 1:200 in milliQ-water and 2 μl of each dilution was mixed with 10 μl 
of reaction mix (1 ml Hi-Di mixed with 2.5 μl size standard). Fragment analysis 
runs were performed with ABI3730xl DNA analyzer. Data was analyzed by 
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measuring ratio of amplified peak heights and areas between wildtype FLT3 and 
FLT3-ITD with GeneMapper v5.  
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Experimental BALB/c BM cells were fixed with 1.5% formaldehyde for 15 
minutes at +37°C and permeabilized with 100% methanol (30 minutes at -20°C). 
The permeabilized cells were washed with 1xPBS and stained using Alexa 647-
anti-phospho-Stat5 (pY694) and PE-anti-phospho-Erk1/2 (pT202/pY204) (BD 
Biosciences) antibodies. The samples were run on IntelliCyt iQUE Screener 
PLUS instrument (Sartorius, Göttingen, Germany) and data analyzed with FlowJo 
software version 10 (TreeStar, San Carlos, CA, USA). 
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All statistical analyses were performed in GraphPad Prism version 6 (GraphPad 
Software, La Jolla, CA, USA). In study I, alternatively spliced intragenic regions 
were compared between NUP98-NSD1+ and negative samples using unpaired 
nonparametric Mann-Whitney U tests. In study II, correlation analyses were done 
using Spearman’s rank correlation coefficient method, and the DSS comparisons 
between patients and healthy BM MNCs using Mann-Whitney U test. The gene 
expression values (log2 CPM) were compared between different samples using 
unpaired two-sample t tests. In all statistical tests, two-tailed P values below 0.05 
were considered significant.  
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Due to submicroscopic size and localization in the subtelomere region, 
t(5;11)(q35;p15.4) translocation cannot be captured with routine G-banding. The 
detection of this chromosomal aberration relies on accurate molecular monitoring 
methods such as FISH, RT-PCR or RNA-Seq. In study I, our aim was to facilitate 
the molecular detection of NUP98-NSD1 from AML patients with t(5;11) 
translocation. We focused on RNA splicing, since prior study had reported two 
chimeric NUP98-NSD1 transcripts from a patient with myelodysplastic syndrome 
(11). The index patient for this study was a 54-year old Finnish male from which 
RNA-Seq had revealed a chimeric NUP98-NSD1 fusion gene (149). We initially 
performed A-CGH analysis and found microdeletions within NUP98 at 11p15.4 
and NSD1 at 5q35.2 indicative of unbalanced t(5;11)(q35.2;p15.4) translocation. 
The microdeletions at these sites were 0.11 Mb (chr11: 3,617,261-3,723,126) and 
0.05 Mb (chr5: 176,546,244-176,595,458) in size as shown in Figure 4.  
 
 
 
 
 
 
 
 
 
Figure 4 A-CGH graph shows micro-deletions within NUP98 and NSD1 genes at 11p15.4 
and 5q35.2 from the DNA of index patient compared to reference genome (Hg19). The 
oligos on the left side of moving average (circles) with copy number ratio below -0.5 
indicate sites of heterozygous microdeletions. 
NUP98
deletion
NSD1
deletion
5q35.2
11p15.4
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Based on the A-CGH analysis, we concluded that putative intronic breakpoints 
had occurred in DNA within a probe length (60-mer) from positions 
chr11:3,723,126 (NUP98) and chr5:176,595,458 (NSD1). We subsequently 
cloned full-length NUP98-NSD1 sequences from the index patient’s BM MNCs 
into One Shot™ Stbl3™ chemically competent E. coli and Sanger sequenced 
numerous plasmid clones. Two in-frame and one out-of-frame NUP98-NSD1 
transcripts were found, which were 5,676, 5,562, and 5,432 nucleotides in length. 
Sequence alignment showed two alternative fusion junctions joining NUP98 exon 
12 to NSD1 exon 6 and NUP98 exon 11 to NSD1 exon 6. We also captured 
alternative 5’ donor site from NUP98 exon 7 (nucleotides 757-783, amino acids 
QNKTAFGTS) and skipping of NSD1 exon 7 (nucleotides 3922-4192) (Figure 
5A). The nucleotide numbers were calculated from the first ATG start codon of 
NCBI reference sequences NM 139131.3 and NM 022455.4.  
 
We searched for additional knowledge about the potential functional 
consequences of splice events by converting NUP98-NSD1 sequences into amino 
acid sequences using EMBOSS Transeq. The two in-frame transcripts harbored 
same NSD1 functional domains, while the out-of-frame NUP98-NSD1 transcript 
lacked all C-terminal domains of NSD1 due to early stop codon. As shown in 
Figure 5, the number of FG repeats varied between 38, 36, and 39 in the three 
different NUP98-NSD1 fusion proteins. The tentative amino acid lengths of the 
three different NUP98-NSD1 fusions were 1891, 1853, and 531, respectively.  
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We re-analyzed RNA-Seq data from index patient since initial alignment had 
exposed only one NUP98-NSD1 fusion transcript. Strikingly, modified alignment 
strategy revealed the expression of novel splice events and confirmed that these 
were not PCR artefacts or RNA-Seq library preparation errors (Figure 6). Of the 
FASTQ reads spanning across fusion junction, the percentage of reads supporting 
NUP98 exon 12 to NSD1 exon 6 fusion was 93% (75/81) in relapse sample 600_2, 
while it was 91% (71/78) in the refractory sample 600_3 collected 2 months later. 
Correspondingly, the percentage of reads supporting NUP98 exon 11 to NSD1 
exon 6 junction increased from 7% (6/81) to 9% (7/78). Encouraged by these 
results, we performed RNA-Seq to three additional samples from two adult AML 
patients with t(5;11). Both fusion junctions were captured from all subsequent 
 
 
 
 
43 
samples confirming that previous studies regarding NUP98-NSD1+ AML had 
overlooked the fusion joining NUP98 exon 11 to NSD1 exon 6. Similar to index 
patient, percentage of reads supporting NUP98 exon 11/NSD1 exon 6 junction 
increased from 9.4% (9/96) to 18.1% (13/72) in patient 3660 during disease 
progression. Concurrently, the relative frequency of the more highly expressed 
NUP98 exon 12/NSD1 exon 6 fusion decreased from 90.6% to 81.9%. In patient 
3600, the NUP98 exon 12 to NSD1 exon 6 fusion was also the predominant 
transcript (Figure 4A). Reciprocal NSD1-NUP98 was not found from any t(5;11)+ 
AML patient indicating 5’-NUP98-NSD1-3’ as the sole initiating oncogene. 
 
 
Figure 5 Three alternatively spliced NUP98-NSD1 transcripts were identified from 
index patient’s leukemic BM cells by cloning and capillary sequencing. (A) The 
schematic drawing shows spliced intragenic areas (NUP98 grey, NSD1 orange) with 
corresponding nucleotide sequences, whereas the lower panel (B) shows protein 
structures. The blue color indicates amino acids belonging to NUP98 and grey those that 
are part of NSD1. The vertical lines (black) represent FG repeats. The distinct protein 
domains are shown for each protein with amino acid lengths. 
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Figure 6 Aligned FASTQ reads. (A) Paired-end reads from the index patient supporting 
the two alternative fusion junctions, (B) alternative 5’ donor site of NUP98 exon 7, and 
(C) skipping of NSD1 exon 7.  
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To study whether intragenic splice events are specific to NUP98-NSD1-positive 
disease, we compared the percentage of intragenic splice events between t(5;11) 
positive (n = 5) and negative samples (n = 16). The t(5;11) negative BM MNCs 
were collected from patients with different hematological malignancies, and from 
CD34+ enriched BM cells of two healthy donors. Interestingly, no differences 
were found in the frequency of alternative 5’donor site of NUP98 exon 7 or NSD1 
exon 7 skipping between NUP98-NSD1+ and NUP98-NSD1 negative patients. The 
intragenic splice events in NUP98 and NSD1 genes were identified from all 
NUP98-NSD1 negative cases. The percentage of reads supporting the alternative 
5’donor site in the NUP98-NSD1+ group (n = 5) was 8% (95% CI 5.3-9.9%), while 
it was 6% (95% CI 5.3-7.4%) in the control group (n = 16). The percentage of 
reads supporting NSD1 exon 7 skipping was 6% (95% CIs 0-13.1% and 3.4-9.4%) 
in both groups. Differences in intragenic splicing of NUP98 or NSD1 were 
insignificant between the positive and negative groups (Figure 7B-C).  
 
Figure 7 FASTQ read counts supporting the two alternative fusion junctions and 
intragenic splice events. (A) The graph shows the total number of read supporting the 
two fusion junctions in three de novo AML patients with the cryptic t(5;11)(q35;p15.4) 
translocation. (B-C) The scatter plots illustrate the percentage (y-axis) of reads supporting 
alternative 5’donor site of NUP98 exon 7 and skipping of NSD1 exon 7 relative to all reads 
covering these exonic regions in NUP98-NSD1+ (N = 5) and NUP98-NSD1- (N = 16) 
patient samples. Error bars show mean with range. 
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In study II, our objective was to discover clinically relevant and more efficient 
treatment options for NUP98-NSD1+/FLT3-ITD+ AML patients. The study was 
initiated by establishing experimental mouse cell lines (BALB/c and BA/F3) that 
express NUP98-NSD1, FLT3-ITD, or both together. We first analyzed differential 
drug sensitivities in the mouse cell lines based on drug mechanism of action. As 
shown in Figure 8, we discovered that leukemic NUP98-NSD1+/FLT3-ITD+ cells 
have significantly lower sensitivity to BCL-2 inhibitors (P = 0.029) compared to 
cells expressing NUP98-NSD1 alone, which had particularly high sensitivity to 
BCL-2 inhibitors. Another striking observation was that dual positive cells have 
significantly higher sensitivity to FLT3 and MEK inhibitors (P < 0.01) compared 
to cells expressing FLT3-ITD alone. Analysing single therapeutic agents from 
these drug classes, we found that pan-BCL-2 inhibitor navitoclax had the highest 
mean sDSS (= 17.5) in the NUP98-NSD1+ mouse cells, while FLT3 inhibitor 
quizartinib (mean sDSS = 22.8) and MEK inhibitor pimasertib (mean sDSS = 
13.2) had the highest efficacy against NUP98-NSD1+/FLT3-ITD+ cells. 
Figure 8 DSRT data showing molecularly specific drug responses in experimental 
mouse cell lines. The numbers below each graph indicate different cell lines: 1, Ba/F3 
NUP98-NSD1; 2, BALB/c NUP98-NSD1; 3, BALB/c FLT3-ITD; 4, BALB/c NUP98-
NSD1 + FLT3-ITD (preleukemic); 5, BALB/c NUP98-NSD1 + FLT3-ITD (leukemic). 
 
To follow-up on the FLT3 and MEK inhibitor sensitivities and learn about the 
biological mechanisms leading to these responses, we performed phospho-flow 
analysis. We evaluated phosphorylation of STAT5 and ERK1/2, since earlier 
studies had shown that co-activation of STAT5 and MAPK-pathways occurs 
1 2 3 4 5
-10
0
10
20
30
Samples
sD
SS
*
BCL2 inhibitors (n = 4)
1 2 3 4 5
-10
0
10
20
30
Samples
sD
SS
****
FLT3 inhibitors (n = 11)
****
1 2 3 4 5
-10
0
10
20
30
Samples
sD
SS **
**
MEK inhibitors (n = 6)
 
 
 
 
47 
downstream of activated FLT3 signaling (161). Intriguingly, the highest 
phosphorylation of STAT5 and ERK1/2 was found in the cells co-expressing 
NUP98-NSD1 and FLT3-ITD coinciding with the highest FLT3 and MEK 
inhibitor sensitivities observed in those cells.  
/,,+7+39/'1*7:-8+38/9/;/9/+8/357/2'7>)+118
We next performed DSRT on primary BM MNCs from AML patients and healthy 
donors to learn more about the drug sensitivities in NUP98-NSD1+/FLT3-ITD+ 
patients (Figure 9). The index patient was tested with 171 drugs and other three 
patients with 306 drugs. By analysing commonly tested drugs between patients 
and healthy donors, we observed that 58% (99/171) of drugs were more effective 
in patients than in healthy cells, 30% (51/171) had no response (DSS = 0), and 
12% (21/171) had negative median DSS difference suggesting drug resistance.  
Figure 9 Waterfall plots showing differential drug sensitivities in AML patients with 
NUP98-NSD1 and FLT3-ITD. Horizontal bars highlight the 20 most and least effective 
drugs in four patients compared to median DSS of ten healthy donors. The drugs marked 
with an asterisk were not tested in the index patient. Two samples were collected at 
diagnosis (D) and two at relapse (R).  
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As shown in Table 6, 15% (25/171) of the tested drugs had significant (P < 0.01) 
median DSS difference between NUP98-NSD1+/FLT3-ITD+ AML patients and 
healthy donors (Table 1). The drugs included one probe, 19 investigational drugs, 
and five clinically approved drugs. Of the approved drugs, dasatinib had the 
highest specificity toward NUP98-NSD1+/FLT3-ITD+ cells (median DSS 
difference: 16.3) and the lowest mean IC50 (2.2 nM, 95% CI -1.4-5.8 nM). Only 
one drug (mitoxantrone) had negative DSS difference, however, several 
topoisomerase inhibitors had negative DSS difference indicating that NUP98-
NSD1+/FLT3-ITD+ cells may be intrinsically resistant to this class of drugs.  
 
 
Table 6. The most differentially sensitive drugs between NUP98-NSD1+/FLT3-ITD+ AML 
patients and healthy controls (P < 0.01).  
DRUG NAME MOLECULAR TARGET STATUS DSS MEDIAN 
DIFFERENCE 
95%CI DSS  
(PATIENTS) 
95%CI DSS  
(HEALTHY) 
P 
VALUE 
AZD8055 mTOR Phase 1 20.5 (4.1, 38.9) (1.1, 5.6) 0.004 
REFAMETINIB MEK1/2 Phase 1/2 19.6 (8.3, 26.8) (0.0, 3.0) 0.002 
TIVOZANIB FLT3, VEGFR1-3, c-Kit, PDGFR Phase 2 18.7 (11.5, 28.9) (-0.3, 6.4) 0.001 
IDELALISIB PI3K, p110 δ-selective Phase 3 17.4 (4.4, 32.5) (1.1, 3.9) 0.004 
PIMASERTIB MEK1/2 Phase 2 17.1 (6.2, 24.7) (0.3, 3.2) 0.002 
DASATINIB ABL1, c-KIT, SRC, LCK Approved 16.3 (11.9, 23.2) (-0.2, 7.1) 0.003 
BIIB021 HSP90 Phase 2 16.2 (21.5, 27.8) (7.0, 9.8) 0.002 
NAVITOCLAX BCL-2, BCL-xL, BCL-w, BCL2A1, MCL-1 Phase 2 12.4 (12.1, 41.1) (9.6, 12.8) 0.002 
LESTAURTINIB FLT3, JAK2, TrkA-C Phase 3 11.6 (9.6, 20.4) (3.0, 6.6) 0.002 
DORAMAPIMOD pan-p38 MAPK, c-RAF, FYN, LCK Phase 1/2 11.3 (4.9, 19.9) (0.0, 3.6) 0.001 
FORETINIB MET, VEGFR2 Phase 2 10.8 (3.1, 25.8) (2.9, 5.0) 0.004 
AZD7762 Chk1 Probe 10.3 (7.5, 24.3) (5.3, 8.3) 0.008 
LUMINESPIB HSP90 Phase 2 10.2 (21.4, 26.7) (11.5, 15.8) 0.002 
OSI-027 mTOR Phase 1 9.9 (6.7, 18.7) (0.6, 4.2) 0.002 
LINSITINIB IGF1R, IR Phase 2 9.5 (3.2, 17.0) (0.6, 3.3) 0.004 
TANESPIMYCIN HSP90 Phase 2 9.2 (12.6, 24.3) (7.0, 9.6) 0.002 
EVEROLIMUS mTOR Approved 8.2 (2.8, 14.0) (-0.5, 2.6) 0.002 
BELINOSTAT HDAC Phase 2 7.2 (20.9, 29.3) (15.3, 18.3) 0.002 
AXITINIB VEGFR, PDGFR, KIT Approved 5.2 (2.6, 14.9) (1.6, 4.3) 0.004 
DANUSERTIB Aurora kinase A-C, Abl, c-RET, LCK Phase 2 4.9 (10.6, 13.5) (4.7, 8.1) 0.002 
ENTINOSTAT HDAC Phase 2 4.9 (2.5, 20.4) (3.9, 5.8) 0.004 
PICTILISIB PI3Kα/δ  Phase 2 4.5 (8.9, 16.7) (6.5, 8.5) 0.002 
PANOBINOSTAT HDAC Phase 3 4.2 (22.9, 30.3) (19.4, 22.6) 0.002 
VORINOSTAT HDAC Approved 4.2 (9.0, 15.4) (5.8, 9.0) 0.002 
MITOXANTRONE Topoisomerase II Approved -6.3 (-2.0, 5.8) (5.9, 8.6) 0.008 
 
 
To study NUP98-NSD1+/FLT3-ITD+ specificity further, we compared median 
DSSs between NUP98-NSD1+/FLT3-ITD+ (n = 4) and NUP98-NSD1-/FLT3-ITD+ 
(n = 9) BM MNC samples. Three drugs, namely dasatinib (P = 0.03), belinostat 
(P = 0.02), and tivozanib (P = 0.03), had significantly higher sensitivity in the 
NUP98-NSD1+/FLT3-ITD+ samples compared to NUP98-NSD1-/FLT3-ITD+ 
samples, while topoisomerase II inhibitor mitoxantrone had significantly lower 
sensitivity (Figure 10). We also evaluated the impact of blast percentage on 
differential drug sensitivities since NUP98 rearrangements have been shown to 
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affect CD34+ progenitor cells in myeloid and lymphoid leukemias (138). We 
found that dasatinib sensitivity correlates positively (R = 0.800) with BM blast 
percentage in the NUP98-NSD1+/FLT3-ITD+ BM MNCs, but not in NUP98-
NSD1-/FLT3-ITD+ cells (R = 0.25) (Figure 11). Based on these results, dasatinib 
was selected for combinatorial drug synergy screening experiments.  
 
 
 
Figure 10 The graph shows 
comparison of ex vivo drug 
sensitivities of top candidate 
compounds in healthy controls, 
FLT3-ITD+ AML BM MNCs and 
NUP98-NSD1+/FLT3-ITD+ BM 
MNCs. Significant differences are 
denoted with an asterisk (*, P < 0.05; 
**, P < 0.01). 
 
 
 
 
 
 
 
 
 
Figure 11 Dasatinib sensitivity 
correlates with malignant cell 
percentage. The graph illustrates ex 
vivo dasatinib sensitivity (Y-axis) 
and relative frequency of BM blast 
cells in AML patients at the time of 
BM sampling. Correlation 
coefficients (R-score) are shown 
above the linear regression line.  
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Pilot combinatorial drug screening experiments were done with experimental 
mouse cell lines. By testing 70 compounds ± 100nM dasatinib, we observed that 
multikinase inhibitor dasatinib improves FLT3 and MEK inhibitor efficacies 
significantly in the NUP98-NSD1+/FLT3-ITD+ cells (Figure 12), but not in other 
cell types.  
 
Figure 12 Pilot combination screen. (A) The heatmap shows DSS of 70 drugs ± 100 nM 
dasatinib in experimental cell lines. (B-C) The histograms show mean DSS with 95% CI. 
Significant differences were found in dual NUP98-NSD1+/FLT3-ITD+ BALB/c cells for 
FLT3 and MEK inhibitors (*, P =0.02; **, P < 0.01). (D) NUP98-NSD1+ cells had high 
BCL-2 inhibitor sensitivity, however, 100 nM dasatinib increased response only modestly.  
 
 
To investigate potentially synergistic drug pairs further, we selected eleven drug 
pairs from the pilot screen for more systematic analysis with 88 and 66 
pairwise matrices. Notably, we discovered that multikinase inhibitor dasatinib 
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shows the strongest synergistic interactions with pan-BCL-2 inhibitor navitoclax 
in NUP98-NSD1+/FLT3-ITD+ primary patient cells and leukemic dual positive 
mouse cells. As shown in Figure 13, the most synergistic area scores in patient 
600, 7499, and leukemic BALB/c cells were 14.0, 6.1, and 9.4, respectively. In 
both patients, the highest ex vivo synergy was observed at an area where 0.1 nM 
dasatinib was combined with 30-300 nM navitoclax (56-62% inhibition). The 
highest synergy score was observed in leukemic mouse cells when 3 nM dasatinib 
was combined with 300 nM navitoclax. 
Figure 13 Synergy plots. The 2-dimensional contour plots show areas of synergy (red) 
and antagonism (green) in primary patient cells and experimental cell lines when tested 
with different concentrations of dasatinib and navitoclax. The white squares indicate the 
most synergistic area. 
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To investigate biological mechanisms underlying observed drug sensitivities, we 
performed RNA-Seq to patient-derived BM MNCs, BM CD34+ cells from 
healthy controls, and experimental BALB/c BM cells. Initially, we evaluated the 
expression of HOX-cluster genes since overexpression of these genes is a known 
feature of NUP98-NSD1+ AML (116, 124, 129). In consonance with previous 
studies, we found that NUP98-NSD1+/FLT3-ITD+ patients overexpress HOX-A9, 
HOX-A10, HOX-B3, -B4, -B5, -B6, and -B7 genes relative to normal CD34+ cells. 
More importantly, by sequencing experimental BALB/c cells, we confirmed the 
findings of Wang et al who reported earlier that NUP98-NSD1 alone induces 
constitutive expression of many HOX cluster genes (129). As expected, FLT3-
ITD alone did not induce HOX genes (Figure 14 A-B).  
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Figure 14 Transcriptome analysis. Unsupervised hierarchical clustering of HOX-AB 
cluster genes was done using 16 primary BM samples (A) and five experimental BALB/c 
cell lines (B) based on mean centered and log2 transformed expression values (Log2 CPM) 
using Euclidean distance with complete linkage method. Heatmaps were drawn with R 
package pheatmap (1.0.8). (C-F) The lower panels show the RNA-level expression of 
dasatinib and navitoclax targets in human and mouse samples. The asterisks define levels 
of statistical significance (*, P = 0.028; **, P = 0.006; ***, P = 0.0006). 
 
 
We next compared the log2-transformed (Log2 CPM) expression levels of various 
dasatinib and navitoclax target proteins relative to healthy CD34+ BM cells. 
Although number of dissimilarities were observed, LCK (P = 0.005), FGR (P < 
0.001), and BCL2A1 (P = 0.028) were the only significantly overexpressed genes 
(Figure 11C-D). Statistical analyses could not be performed on experimental 
BALB/c cells; however, data strongly suggests that NUP98-NSD1 alone may 
induce BCL2A1 expression (Figure 14F). The data shows that BCL-2 inhibitor 
resistant leukemic NUP98-NSD1+/FLT3-ITD+ BALB/c cells have the highest 
expression of anti-apoptotic MCL-1, although connection between BCL-2 
inhibitor resistance and increased MCL-1 expression remains undetermined. To 
learn more about the potential causes of high dasatinib sensitivity, we evaluated 
phosphorylation of several SRC family kinases from phosphokinase antibody 
array analysis previously performed on index patient (149). Intriguingly, 
phosphorylation of LCK, FYN, and LYN was increased in NUP98-NSD1+/FLT3-
ITD+ index patient compared to healthy controls in samples collected at three 
different time-points (Figure 15). 
 
 
 
 
 
 
 
Figure 15 Phosphokinase antibody array results. The graph shows phosphorylation 
status of several SRC family kinases in three samples from the index’s patient relative to 
healthy control.  
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The aim of study (I) was to discover whether previously unknown NUP98-NSD1 
fusion transcripts are expressed in AML patients with cytogenetically silent 
t(5;11) translocation and to learn whether current molecular monitoring methods 
for NUP98-NSD1 need improvement. The questions were based on previous 
work, which had discovered two chimeric NUP98-NSD1 transcripts from an adult 
refractory anemia (RAEB) patient with excess blasts (11). RAEB frequently 
proceeds to AML (162), so we anticipated that novel NUP98-NSD1 transcripts 
may exist in AML as well. Another reason prompting us to study this particular 
aberration was that translocation t(5;11) is undetectable by routine cytogenetic 
methods (G-banding) due to its cryptic nature and subtelomeric localization. The 
detection of t(5;11) therefore relies on robustly designed molecular screening 
methods.  
 
By utilizing standard molecular cloning and NGS methods, we generated evidence 
showing that post-transcriptional processing of NUP98-NSD1 produces three 
alternative mRNA transcripts in AML (140). From these transcripts, we found two 
fusion junctions (juxtaposing NUP98 exon 11/12 to NSD1 exon 6), alternative 5’ 
donor site of NUP98 exon 7 and differentially spliced NSD1 exon 7. We 
discovered that the previously unknown intragenic splice events involving NUP98 
exon 7 and NSD1 exon 7 were present in healthy controls (N = 2) and patients 
without NUP98-NSD1 (N = 10). This finding suggest that these events are normal 
post-transcriptional RNA modifications of wild type genes, which retain splicing 
activity upon acquisition of the t(5;11) translocation.  
 
With sequential samples available from two patients, we found that NUP98-
NSD1+ fusion was present at relapse and chemorefractory stage (Figure 7A). The 
finding is consistent with a study describing NUP98-NSD1 as a clonally stable 
founder alteration and notion that its increasing expression correlates with 
hematological relapse (116, 122). Consistently, Ostronoff et al has demonstrated 
association between NUP98-NSD1 and chemoresistance by showing that most 
NUP98-NSD1+ AML patients remain positive for the fusion at the end of first 
cycle of induction chemotherapy leading to high-rate of induction failure (120). 
 
 
 
 
55 
These studies confirm the role of NUP98-NSD1 as a clinically relevant marker, 
not only for prognostication, but also for determining treatment efficacy and 
presence of minimal residual disease.  
 
The co-expression of two alternative NUP98-NSD1 transcripts (NUP98 exon 
11/12 to NSD1 exon 6) detected in our study were present in all three NUP98-
NSD1+ study patients. In a follow-up analysis of two similar patients (data not 
shown) from TCGA AML cohort (4), however, the transcript joining NUP98 exon 
11 and NSD1 exon 6 was not found. We think that the RNA-Seq coverage in the 
TCGA analysis may have been too low to expose supporting reads for the less 
frequent transcript or that there is heterogeneity in the NUP98-NSD1 transcript 
levels between patients. The latter idea is supported by Shiba et al who identified 
sole expression of NUP98 exon 11 and NSD1 exon 6 fusion from a NUP98-NSD1-
like pediatric AML patient (124). In favor of both ideas, a recent study by 
Audemard et al repeated our findings and reported co-expression of two in-frame 
NUP98-NSD1 transcripts from 6 AML patients. Intriguingly, in their analysis one 
patient expressed only the well-known fusion between NUP98 exon 12 and NSD1 
exon 6 (163). Taken together, results from available studies imply that in spite of 
few outliers, majority of AML patients with NUP98-NSD1 co-express at least two 
in-frame NUP98-NSD1 transcripts (NUP98 exon 11/12 to NSD1 exon 6). We 
conclude that adjustment of oligonucleotide probes to detect both fusion junctions 
(NUP98 exon 11/12 to NSD1 exon 6) is important to ensure all patients with 
NUP98-NSD1 are appropriately identified during pre-diagnostic screening. This 
adjustment will not only improve the accuracy of MRD quantification at post-
treatment follow-up, but will also teach us whether frequencies of the two 
alternative NUP98-NSD1 transcripts may fluctuate in response to treatment and 
play role in drug resistance.  
 
Few limitations to study I need to be acknowledged. Firstly, the presented results 
should be confirmed in larger series of NUP98-NSD1+ AML patients in order to 
draw stronger conclusions. Our analysis was limited to three adult patients due to 
infrequency of NUP98-NSD1 fusion gene in AML and low overall incidence of 
AML in Finland. In a study published in 2012, NUP98-NSD1 was identified from 
roughly 2% and 16% of adult and pediatric CN-AML patients, respectively (116). 
The relative frequency of NUP98-NSD1 in Finnish population has not been 
systematically analysed. Based on the observed frequencies in other countries, our 
findings may have more importance for the management of pediatric rather than 
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adult AML patients. Secondly, we did not perform mechanistic studies to evaluate 
whether the identified in-frame NUP98-NSD1 transcripts may convey different 
leukemogenic functions. Based on in silico analysis of structural domains (Figure 
5B), the differences are expected to be minimal and limited to three FG repeats 
located in NUP98 exons 7 and exon 12. Other than disparities in FG repeat count, 
all functional domains remained consistent between the two in-frame transcripts. 
We envision that on-going work at John Hopkins University with the plasmids we 
generated will shed light on functional differences between the two NUP98-NSD1 
transcripts. Thirdly, our RNA-Seq analysis identified additional anomalies, which 
could not be validated by cloning and Sanger sequencing. These anomalies 
included single read for RNA joining NUP98 exon 6 to NSD1 exon 12 and five 
reads to RNA joining NUP98 exon 8 to NSD1 exon 11. The analysis also revealed 
potential low-level transcripts joining NUP98 exon 11 to NSD1 exon 17 and exon 
21. Whether these variants are real or artefacts remain to be determined. Based on 
the observation, however, we acknowledge that additional, currently unknown 
NUP98-NSD1 transcripts may be generated in patients with t(5;11) translocation. 
 
Additionally, it remains unclear whether the two in-frame NUP98-NSD1 
transcripts or their distribution may affect therapeutic responses and 
hematological parameters. Based on evidence from BCR-ABL1 fusion gene, this 
may be relevant question. A study by Adler et al revealed equal distribution of 
coexpressed b2a2 (e13a2) and b3a2 (e14a2) transcripts between genders, whereas 
the sole expression of either form showed uneven distribution. In the same study, 
higher platelet count in conjunction with leukocytosis was more frequent in 
patients expressing the b3a2 transcript (164). Furthermore, two independent 
studies have shown that uneven distribution of b2a2 and b3a2 transcripts impacts 
molecular response to imatinib (165, 166). Analogous to BCR-ABL1, alternative 
NUP98-NSD1 transcripts could distribute unevenly between population 
subgroups or influence distinct hematological parameters and therapy. Future 
study with a larger cohort of NUP98-NSD1+ patients, such as the COG trial cohort 
(N = 32) or the French pediatric cohort (N = 17) of NUP98-NSD1+ pediatric AML 
patients (120, 126), should explore the NUP98-NSD1 transcripts further for 
revealing transcript distributions as well as their therapeutic implications (should 
patient material be available). 
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In study II, our aim was to discover novel treatment options for high-risk AML 
patients with concomitant NUP98-NSD1 fusion gene and FLT3-ITD using high-
throughput drug screening and NGS methods. The main motivation for starting 
the project was that majority of NUP98-NSD1+/FLT3-ITD+ AML patients never 
achieve CR (144) and those that do, eventually become chemoresistant (120). Due 
to chemoresistance and high rate of relapse (116), it is crucial to find novel 
therapeutics for this patient subset. Using state-of-the-art technologies, we 
acquired evidence indicating that NUP98-NSD1+/FLT3-ITD+ patients may benefit 
from combinatorial treatment with multikinase inhibitor dasatinib and pan-BCL-
2 inhibitor navitoclax. Dasatinib and navitoclax targeted NUP98-NSD1+/FLT3-
ITD+ BM MNCs selectively as single agents and synergistically in combination 
(Figure 13). Additional drug classes with selective efficacy against NUP98-
NSD1+/FLT3-ITD+ BM MNCs included HDAC inhibitors, FLT3 inhibitors, and 
inhibitors of MAP kinase and PI3K/AKT pathways (Table 6).  
 
In the DSRT assay, dasatinib was the most selective drug for NUP98-
NSD1+/FLT3-ITD+ BM MNCs. Dasatinib (BMS-354825) is a multikinase 
inhibitor targeting BCR-ABL, SRC family (SRC, LCK, FGR, YES, FYN), c-KIT, 
EPHA2, and PDGFRβ. It has FDA approval for the treatment of CML and ALL, 
and is currently being evaluated in a phase III clinical trial with and without 
chemotherapy for adult core binding factor AML (NCT02013648). The phase III 
trial was initiated following a successful phase Ib/IIa study (167). Consistent with 
known drug targets, we discovered that dasatinib sensitivity in NUP98-
NSD1+/FLT3-ITD+ BM MNCs may result from increased expression of LCK or 
FGR genes (Figure 14). Out of the two genes, LCK appears to be most relevant as 
we found three LCK targeting drugs (dasatinib, doramapimod, danusertib) among 
the top hits (Table 6). The relevancy of LCK in NUP98-NSD1-driven 
leukemogenesis is also supported by our expression analysis on mouse cells, 
which showed that NUP98-NSD1 alone may induce LCK expression (Figure 
14E). Interestingly, NUP98-NSD1 and LCK have both been shown to cooperate 
with FLT3-ITD in cellular transformation (146, 168). Therefore, hypothetical 
connection between NUP98-NSD1 and LCK appears highly interesting and worth 
studying in more detail.  
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To date, no cancer pharmacopeia-wide drug screening studies have been done on 
NUP98-NSD1+/FLT3-ITD+ AML samples. Therefore, we are limited to 
interpreting our findings in the light of mechanistic studies performed on NUP98 
rearrangements and structurally similar MLL rearrangements (169). A common 
theme, which clearly emerges is that epigenetic dysregulation may lead to highly 
selective BCL-2 inhibitor sensitivities in NUP98-NSD1+ AML cells. Fairly recent 
work by Benito et al found BCL-2 to be a direct transcriptional target of MLL-
AF4. They showed that MLL-AF4 upregulates BCL-2 by DOT1L-mediated 
H3K79 methylation activity, which leads to high BCL-2 inhibitor (venetoclax) 
sensitivity (170). Congruently, abnormal H3K79 and H3K36 methylation 
activities have been shown to be vital for NUP98-NSD1-dependent 
leukemogenesis as well (129, 134). Another line of evidence linking aberrant 
methylation activities of NUP98-NSD1 to antiapoptotic BCL-2 family members 
relates to activation of NF-κB. Studies have demonstrated that, through lysine 
methylation, NSD1 activates p65 subunit of NF-κB (171), which directly controls 
BCL2A1 expression (172). It remains unstudied whether this function of NSD1 is 
retained in the NUP98-NSD1 fusion. Since BCL2A1 was the only significantly 
upregulated antiapoptotic BCL-2 family member in our study (Figure 14D), the 
scheme seems highly plausible. Based on the above-mentioned findings, we 
picture that the highly selective BCL-2 inhibitor responses observed in NUP98-
NSD1+/FLT3-ITD+ AML cells may arise as a result of NUP98-NSD1-mediated 
aberrant histone methylation that activate antiapoptotic BCL-2 family members 
such as BCL2A1. Future studies should study the potential connection between 
aberrant lysine methylation and BCL-2 inhibitor sensitivity in AML patients with 
NUP98-NSD1 fusion gene as well as structurally similar NUP98 rearrangements. 
Moreover, potential efficacy of BCL-2 inhibitor venetoclax should be evaluated 
in prospective studies as navitoclax is currently unavailable for clinical use. 
 
Curiously, we observed striking differences in BCL-2 inhibitor responses between 
NUP98-NSD1+/FLT3-ITD+ patient cells and mouse progenitor cells co-transduced 
with NUP98-NSD1 and FLT3-ITD indicating our mouse model does not fully 
reflect the molecular complexities present in human cells. The patient cells were 
highly sensitive to BCL-2 inhibitors similar to mouse cells transduced with 
NUP98-NSD1 alone, while the leukemic dual positive mouse cells were BCL-2 
inhibitor resistant (Figure 8). Based on these discrepancies, additional aspects to 
BCL-2 inhibitor responses in NUP98-NSD1+/FLT3-ITD+ BM MNCs need to be 
considered. One relevant aspect could be WT1 mutations. Exome sequencing 
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performed on two of the study patients revealed hotspot mutations in the DNA-
binding domain of WT1 gene. Recent work has shown that up to 45% of NUP98-
NSD1+ AML patients have WT1 mutations (116, 120) and that patients with WT1 
mutations have significantly increased sensitivity to BCL-2 inhibitor venetoclax 
(173). It remains unclear how WT1 mutations mediate increased BCL-2 inhibitor 
sensitivity. Based on Morrison et al, WT1 mutant proteins may fail to activate 
programmed apoptosis by not being able to induce proapoptotic BAK expression 
(174). This inability may tip the balance between pro-and antiapoptotic BCL-2 
members to favor antiapoptotic proteins. To follow-up on these responses, it 
would be relevant to develop a triple positive (NUP98-NSD1+/FLT3-ITD+/WT1+) 
mouse cell line and evaluate whether WT1 mutation resensitizes BCL-2 inhibitor 
resistant leukemic NUP98-NSD1+/FLT3-ITD+ mouse cells to BCL-2 inhibitors. 
Moreover, this model would inform how WT1 mutant protein impact expression 
of pro- and antiapoptotic BCL-2 proteins in cells coexpressing NUP98-NSD1 and 
FLT3-ITD.   
 
Four HDAC inhibitors (belinostat, entinostat, panobinostat, and vorinostat) were 
among the 24 most selective compounds targeting NUP98-NSD1+/FLT3-ITD+ 
BM MNCs. Intriguingly, Kasper et al demonstrated already two decades ago that 
NUP98 rearrangement (NUP98-HOXA9) recruits CREB-binding protein 
(CBP)/p300 histone acetyltransferase, which physically interacts with FG repeat 
rich areas of NUP98 (175). Later work by Wang and colleagues showed with 
NUP98-NSD1+ mouse progenitors that CBP/p300 mediated acetylation of H3/H4 
around HoxA7-A9 locus is a key step (together with H3K36 methylation) in the 
prevention of EZH2-mediated transcriptional silencing of HOX cluster genes 
(129). Regardless of earlier findings, it remains unclear whether HDAC inhibitors 
may reverse aberrant histone acetylation at HOXA7-A9 locus and silence 
constitutively active HOX genes in NUP98-NSD1+ leukemic cells. Based on the 
high ex vivo efficacy of HDAC inhibitors observed in our study, future studies 
should explore the functional impact of these inhibitors further in the context of 
NUP98-NSD1+/FLT3-ITD+ AML.  
 
Another interesting feature of our data was that dual positive transgenic BALB/c 
BM cells had significantly higher sensitivity to FLT3 inhibitors (n = 11) compared 
to cells expressing FLT3-ITD alone (Figure 8). This seems to confirm the 
previously proposed functional cooperation between NUP98-NSD1 and FLT3-
ITD in AML induction (146). In line with the findings of Thanasopoulou et al, 
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functional cooperation between NUP98-HOXD13 and FLT3-ITD, as well as 
between MLL-AF9 and FLT3-ITD in AML induction have been reported (176, 
177). It is therefore likely that our findings regarding FLT3 inhibitors could be 
expanded to other functionally cooperative mutation pairs. Regardless of the 
promising FLT3 inhibitor efficacies observed in vitro, the ex vivo efficacies were 
not as encouraging. Only two (2/6) non-specific FLT3 inhibitors (tivozanib, 
lestaurtinib) reached statistically significant responses in NUP98-NSD1+/FLT3-
ITD+ AML cells and were less effective than multikinase inhibitor dasatinib. 
Similar responses have been observed in the clinic between these compounds. The 
differences in FLT3 inhibitor efficacies between mouse cell lines and patient cells 
may result from differences in FLT3-ITD expression levels. Notably, retroviral 
transduction frequently results in super-physiologic levels of transgene expression 
(178). In our study, we did not compare relative FLT3-ITD expression levels 
between patient cells and mouse cell lines to learn if FLT3 inhibitor sensitivity 
differences are related to expression-levels. According to Pratz et al, FLT3-
mutational load predicts responses to FLT3 inhibitors, particularly in relapse 
samples (100). In their work, highest FLT3 inhibitor sensitivities were found in 
patient samples with high mutant allelic burden (above 50%). In our study, 
NUP98-NSD1+/FLT3-ITD+ AML samples had low (17-40%) FLT3 allelic burden 
(Table 4), which could explain the low ex vivo FLT3 inhibitor sensitivities. 
Accordingly, future work should evaluate the efficacy of FLT3 inhibitors further 
in respect to relapsed NUP98-NSD1+ AML patients with high FLT3-ITD mutation 
load. 
 
Few limitations to our study need to be acknowledged. Firstly, our findings should 
be confirmed in larger series of NUP98-NSD1+/FLT3-ITD+ AML patients since 
only four NUP98-NSD1+ AML patients were tested. We compensated for this 
limitation by including two separate control groups (healthy samples and AML 
patients with FLT3-ITD) and by testing experimental BALB/c cell lines. 
Secondly, drug sensitivity assessment should have been performed using fresh, 
treatment naïve BM MNCs, with equal number of drugs. Two of our samples were 
collected after induction therapy and two were tested after cryopreservation. Three 
BM MNC samples were tested with 306 drugs and one sample with 171 drugs. 
Finally, molecular profiling experiments should have been performed to all 
NUP98-NSD1+/FLT3-ITD+ study patients. In our study, RNA-Seq was executed 
to 3 out of 4 patients and exome sequencing to 2 out of 4. Had this data been 
available, we could be more certain about the deregulated genes associated with 
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NUP98-NSD1-driven AML, their impact on drug responses, and presence of 
additional comutations. In summary, the results presented in study II improves the 
current understanding of potentially efficient treatments for AML patients with 
concomitant NUP98-NSD1 and FLT3-ITD. These data provide a reference point 
for future studies regarding this topic as well as proof-of-concept clinical studies.  
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In this thesis, we used RNA-Seq and standard molecular biology methods to 
characterize alternative NUP98-NSD1 fusion transcripts from AML patients with 
cryptic t(5;11)(q35;p15.4) translocation. Moreover, we investigated novel 
therapeutic opportunities for patients with NUP98-NSD1 and concomitant FLT3-
ITD alteration using high-throughput DSRT and NGS. The primary conclusions 
from these studies are as follows: 
 
 
1. Post-transcriptional modification generates at least three NUP98-NSD1 
mRNA transcripts from NUP98-NSD1 gene fusion in AML patients with 
t(5;11). Distinctive features within the three transcripts include two 
alternative fusion junctions juxtaposing either NUP98 exon 11 or 12 to 
NSD1 exon 7, alternative 5’ donor site at NUP98 exon 7, and skipping of 
NSD1 exon 7. Based on these findings, previously unknown transcript 
joining NUP98 exon 11 to NSD1 exon 7 should be considered in the 
design of molecular monitoring tests for this prognostically significant 
aberration.  
 
2. Multikinase inhibitor dasatinib and pan-BCL-2 inhibitor navitoclax target 
NUP98-NSD1+/FLT3-ITD+ AML patient cells selectively as single agents 
and synergistically in combination. NUP98-NSD1+/FLT3-ITD+ BM 
MNCs are highly resistant to conventional chemotherapeutics such as 
type II topoisomerase inhibitors.  
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